A condition of abnormally elevated output of PARATHYROID HORMONE (or PTH) triggering responses that increase blood CALCIUM. It is characterized by HYPERCALCEMIA and BONE RESORPTION, eventually leading to bone diseases. PRIMARY HYPERPARATHYROIDISM is caused by parathyroid HYPERPLASIA or PARATHYROID NEOPLASMS. SECONDARY HYPERPARATHYROIDISM is increased PTH secretion in response to HYPOCALCEMIA, usually caused by chronic KIDNEY DISEASES.
A condition of abnormally elevated output of PARATHYROID HORMONE due to parathyroid HYPERPLASIA or PARATHYROID NEOPLASMS. It is characterized by the combination of HYPERCALCEMIA, phosphaturia, elevated renal 1,25-DIHYDROXYVITAMIN D3 synthesis, and increased BONE RESORPTION.
Abnormally elevated PARATHYROID HORMONE secretion as a response to HYPOCALCEMIA. It is caused by chronic KIDNEY FAILURE or other abnormalities in the controls of bone and mineral metabolism, leading to various BONE DISEASES, such as RENAL OSTEODYSTROPHY.
Excision of one or more of the parathyroid glands.
Tumors or cancer of the PARATHYROID GLANDS.
Two pairs of small oval-shaped glands located in the front and the base of the NECK and adjacent to the two lobes of THYROID GLAND. They secrete PARATHYROID HORMONE that regulates the balance of CALCIUM; PHOSPHORUS; and MAGNESIUM in the body.
A polypeptide hormone (84 amino acid residues) secreted by the PARATHYROID GLANDS which performs the essential role of maintaining intracellular CALCIUM levels in the body. Parathyroid hormone increases intracellular calcium by promoting the release of CALCIUM from BONE, increases the intestinal absorption of calcium, increases the renal tubular reabsorption of calcium, and increases the renal excretion of phosphates.
Abnormally high level of calcium in the blood.
A fibrous degeneration, cyst formation, and the presence of fibrous nodules in bone, usually due to HYPERPARATHYROIDISM.
A benign epithelial tumor with a glandular organization.
Small organic molecules that act as allosteric activators of the calcium sensing receptor (CaSR) in the PARATHYROID GLANDS and other tissues. They lower the threshold for CaSR activation by extracellular calcium ions and diminish PARATHYROID HORMONE (PTH) release from parathyroid cells.
Pathological processes of the PARATHYROID GLANDS. They usually manifest as hypersecretion or hyposecretion of PARATHYROID HORMONE that regulates the balance of CALCIUM; PHOSPHORUS; and MAGNESIUM in the body.
Reduction of the blood calcium below normal. Manifestations include hyperactive deep tendon reflexes, Chvostek's sign, muscle and abdominal cramps, and carpopedal spasm. (Dorland, 27th ed)
A class of G-protein-coupled receptors that react to varying extracellular CALCIUM levels. Calcium-sensing receptors in the PARATHYROID GLANDS play an important role in the maintenance of calcium HOMEOSTASIS by regulating the release of PARATHYROID HORMONE. They differ from INTRACELLULAR CALCIUM-SENSING PROTEINS which sense intracellular calcium levels.
A non-metal element that has the atomic symbol P, atomic number 15, and atomic weight 31. It is an essential element that takes part in a broad variety of biochemical reactions.
Two-ring crystalline hydrocarbons isolated from coal tar. They are used as intermediates in chemical synthesis, as insect repellents, fungicides, lubricants, preservatives, and, formerly, as topical antiseptics.
Decalcification of bone or abnormal bone development due to chronic KIDNEY DISEASES, in which 1,25-DIHYDROXYVITAMIN D3 synthesis by the kidneys is impaired, leading to reduced negative feedback on PARATHYROID HORMONE. The resulting SECONDARY HYPERPARATHYROIDISM eventually leads to bone disorders.
A form of multiple endocrine neoplasia that is characterized by the combined occurrence of tumors in the PARATHYROID GLANDS, the PITUITARY GLAND, and the PANCREATIC ISLETS. The resulting clinical signs include HYPERPARATHYROIDISM; HYPERCALCEMIA; HYPERPROLACTINEMIA; CUSHING DISEASE; GASTRINOMA; and ZOLLINGER-ELLISON SYNDROME. This disease is due to loss-of-function of the MEN1 gene, a tumor suppressor gene (GENES, TUMOR SUPPRESSOR) on CHROMOSOME 11 (Locus: 11q13).
A basic element found in nearly all organized tissues. It is a member of the alkaline earth family of metals with the atomic symbol Ca, atomic number 20, and atomic weight 40. Calcium is the most abundant mineral in the body and combines with phosphorus to form calcium phosphate in the bones and teeth. It is essential for the normal functioning of nerves and muscles and plays a role in blood coagulation (as factor IV) and in many enzymatic processes.
A technetium imaging agent used to reveal blood-starved cardiac tissue during a heart attack.
The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION.
Derivatives of ERGOSTEROL formed by ULTRAVIOLET RAYS breaking of the C9-C10 bond. They differ from CHOLECALCIFEROL in having a double bond between C22 and C23 and a methyl group at C24.
The physiologically active form of vitamin D. It is formed primarily in the kidney by enzymatic hydroxylation of 25-hydroxycholecalciferol (CALCIFEDIOL). Its production is stimulated by low blood calcium levels and parathyroid hormone. Calcitriol increases intestinal absorption of calcium and phosphorus, and in concert with parathyroid hormone increases bone resorption.
Inorganic salts of phosphoric acid.
A clinical syndrome associated with the retention of renal waste products or uremic toxins in the blood. It is usually the result of RENAL INSUFFICIENCY. Most uremic toxins are end products of protein or nitrogen CATABOLISM, such as UREA or CREATININE. Severe uremia can lead to multiple organ dysfunctions with a constellation of symptoms.
An increase in the number of cells in a tissue or organ without tumor formation. It differs from HYPERTROPHY, which is an increase in bulk without an increase in the number of cells.
A condition caused by a deficiency of PARATHYROID HORMONE (or PTH). It is characterized by HYPOCALCEMIA and hyperphosphatemia. Hypocalcemia leads to TETANY. The acquired form is due to removal or injuries to the PARATHYROID GLANDS. The congenital form is due to mutations of genes, such as TBX1; (see DIGEORGE SYNDROME); CASR encoding CALCIUM-SENSING RECEPTOR; or PTH encoding parathyroid hormone.
Therapy for the insufficient cleansing of the BLOOD by the kidneys based on dialysis and including hemodialysis, PERITONEAL DIALYSIS, and HEMODIAFILTRATION.
A vitamin that includes both CHOLECALCIFEROLS and ERGOCALCIFEROLS, which have the common effect of preventing or curing RICKETS in animals. It can also be viewed as a hormone since it can be formed in SKIN by action of ULTRAVIOLET RAYS upon the precursors, 7-dehydrocholesterol and ERGOSTEROL, and acts on VITAMIN D RECEPTORS to regulate CALCIUM in opposition to PARATHYROID HORMONE.
Disorder caused by an interruption of the mineralization of organic bone matrix leading to bone softening, bone pain, and weakness. It is the adult form of rickets resulting from disruption of VITAMIN D; PHOSPHORUS; or CALCIUM homeostasis.
Diseases of BONES.
Decrease, loss, or removal of the mineral constituents of bones. Temporary loss of bone mineral content is especially associated with space flight, weightlessness, and extended immobilization. OSTEOPOROSIS is permanent, includes reduction of total bone mass, and is associated with increased rate of fractures. CALCIFICATION, PHYSIOLOGIC is the process of bone remineralizing. (From Dorland, 27th ed; Stedman, 25th ed; Nicogossian, Space Physiology and Medicine, 2d ed, pp327-33)
A mass of histologically normal tissue present in an abnormal location.
A specialized CONNECTIVE TISSUE that is the main constituent of the SKELETON. The principle cellular component of bone is comprised of OSTEOBLASTS; OSTEOCYTES; and OSTEOCLASTS, while FIBRILLAR COLLAGENS and hydroxyapatite crystals form the BONE MATRIX.
Syndromes resulting from inappropriate production of HORMONES or hormone-like materials by NEOPLASMS in non-endocrine tissues or not by the usual ENDOCRINE GLANDS. Such hormone outputs are called ectopic hormone (HORMONES, ECTOPIC) secretion.
An enzyme that catalyzes the conversion of an orthophosphoric monoester and water to an alcohol and orthophosphate. EC 3.1.3.1.
A condition of abnormally high level of PHOSPHATES in the blood, usually significantly above the normal range of 0.84-1.58 mmol per liter of serum.
The calcium salt of gluconic acid. The compound has a variety of uses, including its use as a calcium replenisher in hypocalcemic states.
Carbonic acid calcium salt (CaCO3). An odorless, tasteless powder or crystal that occurs in nature. It is used therapeutically as a phosphate buffer in hemodialysis patients and as a calcium supplement.
Metabolic bone diseases are a group of disorders that affect the bones' structure and strength, caused by disturbances in the normal metabolic processes involved in bone formation, resorption, or mineralization, including conditions like osteoporosis, osteomalacia, Paget's disease, and renal osteodystrophy.
Condition of induced systemic hypersensitivity in which tissues respond to appropriate challenging agents with a sudden local calcification.
A nutritional condition produced by a deficiency of VITAMIN D in the diet, insufficient production of vitamin D in the skin, inadequate absorption of vitamin D from the diet, or abnormal conversion of vitamin D to its bioactive metabolites. It is manifested clinically as RICKETS in children and OSTEOMALACIA in adults. (From Cecil Textbook of Medicine, 19th ed, p1406)
Hydroxy analogs of vitamin D 3; (CHOLECALCIFEROL); including CALCIFEDIOL; CALCITRIOL; and 24,25-DIHYDROXYVITAMIN D 3.
Disorders in the processing of calcium in the body: its absorption, transport, storage, and utilization.
Procedures that avoid use of open, invasive surgery in favor of closed or local surgery. These generally involve use of laparoscopic devices and remote-control manipulation of instruments with indirect observation of the surgical field through an endoscope or similar device.
Stones in the KIDNEY, usually formed in the urine-collecting area of the kidney (KIDNEY PELVIS). Their sizes vary and most contains CALCIUM OXALATE.
Pathologic deposition of calcium salts in tissues.
Large cells with small irregular nuclei and dense acidophilic granules due to the presence of abundant MITOCHONDRIA. Oxyphil cells, also known as oncocytes, are found in oncocytomas of the kidney, salivary glands, and endocrine glands. In the thyroid gland, oxyphil cells are known as Hurthle cells and Askenazy cells.
A condition of an abnormally low level of PHOSPHATES in the blood.
The amount of mineral per square centimeter of BONE. This is the definition used in clinical practice. Actual bone density would be expressed in grams per milliliter. It is most frequently measured by X-RAY ABSORPTIOMETRY or TOMOGRAPHY, X RAY COMPUTED. Bone density is an important predictor for OSTEOPOROSIS.
Disorders in the processing of phosphorus in the body: its absorption, transport, storage, and utilization.
Cancers or tumors of the MAXILLA or MANDIBLE unspecified. For neoplasms of the maxilla, MAXILLARY NEOPLASMS is available and of the mandible, MANDIBULAR NEOPLASMS is available.
A gamma-emitting radionuclide imaging agent used for the diagnosis of diseases in many tissues, particularly in the gastrointestinal system, cardiovascular and cerebral circulation, brain, thyroid, and joints.
A group of autosomal dominant diseases characterized by the combined occurrence of tumors involving two or more ENDOCRINE GLANDS that secrete PEPTIDE HORMONES or AMINES. These neoplasias are often benign but can be malignant. They are classified by the endocrine glands involved and the degree of aggressiveness. The two major forms are MEN1 and MEN2 with gene mutations on CHROMOSOME 11 and CHROMOSOME 10, respectively.
Surgical removal of the thyroid gland. (Dorland, 28th ed)
Proteins, usually found in the cytoplasm, that specifically bind calcitriol, migrate to the nucleus, and regulate transcription of specific segments of DNA with the participation of D receptor interacting proteins (called DRIP). Vitamin D is converted in the liver and kidney to calcitriol and ultimately acts through these receptors.
Pathological processes of the KIDNEY or its component tissues.
A condition characterized by calcification of the renal tissue itself. It is usually seen in distal RENAL TUBULAR ACIDOSIS with calcium deposition in the DISTAL KIDNEY TUBULES and the surrounding interstitium. Nephrocalcinosis causes RENAL INSUFFICIENCY.
Agents that increase calcium influx into calcium channels of excitable tissues. This causes vasoconstriction in VASCULAR SMOOTH MUSCLE and/or CARDIAC MUSCLE cells as well as stimulation of insulin release from pancreatic islets. Therefore, tissue-selective calcium agonists have the potential to combat cardiac failure and endocrinological disorders. They have been used primarily in experimental studies in cell and tissue culture.
A form of multiple endocrine neoplasia characterized by the presence of medullary carcinoma (CARCINOMA, MEDULLARY) of the THYROID GLAND, and usually with the co-occurrence of PHEOCHROMOCYTOMA, producing CALCITONIN and ADRENALINE, respectively. Less frequently, it can occur with hyperplasia or adenoma of the PARATHYROID GLANDS. This disease is due to gain-of-function mutations of the MEN2 gene on CHROMOSOME 10 (Locus: 10q11.2), also known as the RET proto-oncogene that encodes a RECEPTOR PROTEIN-TYROSINE KINASE. It is an autosomal dominant inherited disease.
Compounds that are used in medicine as sources of radiation for radiotherapy and for diagnostic purposes. They have numerous uses in research and industry. (Martindale, The Extra Pharmacopoeia, 30th ed, p1161)
Bone loss due to osteoclastic activity.
The continuous turnover of BONE MATRIX and mineral that involves first an increase in BONE RESORPTION (osteoclastic activity) and later, reactive BONE FORMATION (osteoblastic activity). The process of bone remodeling takes place in the adult skeleton at discrete foci. The process ensures the mechanical integrity of the skeleton throughout life and plays an important role in calcium HOMEOSTASIS. An imbalance in the regulation of bone remodeling's two contrasting events, bone resorption and bone formation, results in many of the metabolic bone diseases, such as OSTEOPOROSIS.
Care given during the period prior to undergoing surgery when psychological and physical preparations are made according to the special needs of the individual patient. This period spans the time between admission to the hospital to the time the surgery begins. (From Dictionary of Health Services Management, 2d ed)
Form of radioimmunoassay in which excess specific labeled antibody is added directly to the test antigen being measured.
Phosphorus used in foods or obtained from food. This element is a major intracellular component which plays an important role in many biochemical pathways relating to normal physiological functions. High concentrations of dietary phosphorus can cause nephrocalcinosis which is associated with impaired kidney function. Low concentrations of dietary phosphorus cause an increase in calcitriol in the blood and osteoporosis.
A non-neoplastic inflammatory lesion, usually of the jaw or gingiva, containing large, multinucleated cells. It includes reparative giant cell granuloma. Peripheral giant cell granuloma refers to the gingiva (giant cell epulis); central refers to the jaw.
Hormones released from neoplasms or from other cells that are not the usual sources of hormones.
A hereditary syndrome clinically similar to HYPOPARATHYROIDISM. It is characterized by HYPOCALCEMIA; HYPERPHOSPHATEMIA; and associated skeletal development impairment and caused by failure of response to PARATHYROID HORMONE rather than deficiencies. A severe form with resistance to multiple hormones is referred to as Type 1a and is associated with maternal mutant allele of the ALPHA CHAIN OF STIMULATORY G PROTEIN.
Aniline compounds, also known as aromatic amines, are organic chemicals derived from aniline (aminobenzene), characterized by the substitution of hydrogen atoms in the benzene ring with amino groups (-NH2).
A disease marked by repeated episodes of increased bone resorption followed by excessive attempts at repair, resulting in weakened, deformed bones of increased mass. The resultant architecture of the bone assumes a mosaic pattern in which the fibers take on a haphazard pattern instead of the normal parallel symmetry.
A disorder characterized by muscle twitches, cramps, and carpopedal spasm, and when severe, laryngospasm and seizures. This condition is associated with unstable depolarization of axonal membranes, primarily in the peripheral nervous system. Tetany usually results from HYPOCALCEMIA or reduced serum levels of MAGNESIUM that may be associated with HYPERVENTILATION; HYPOPARATHYROIDISM; RICKETS; UREMIA; or other conditions. (From Adams et al., Principles of Neurology, 6th ed, p1490)
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
Creatinine is a waste product that's generated from muscle metabolism, typically filtered through the kidneys and released in urine, with increased levels in blood indicating impaired kidney function.
The major circulating metabolite of VITAMIN D3. It is produced in the LIVER and is the best indicator of the body's vitamin D stores. It is effective in the treatment of RICKETS and OSTEOMALACIA, both in azotemic and non-azotemic patients. Calcifediol also has mineralizing properties.
The transference of a kidney from one human or animal to another.
The return of a sign, symptom, or disease after a remission.
Surgery performed on any endocrine gland.
A peptide hormone that lowers calcium concentration in the blood. In humans, it is released by thyroid cells and acts to decrease the formation and absorptive activity of osteoclasts. Its role in regulating plasma calcium is much greater in children and in certain diseases than in normal adults.
Conditions in which the KIDNEYS perform below the normal level in the ability to remove wastes, concentrate URINE, and maintain ELECTROLYTE BALANCE; BLOOD PRESSURE; and CALCIUM metabolism. Renal insufficiency can be classified by the degree of kidney damage (as measured by the level of PROTEINURIA) and reduction in GLOMERULAR FILTRATION RATE.
Fluoride poisoning, also known as fluoride toxicity, is a condition characterized by symptoms such as nausea, vomiting, diarrhea, and seizures that result from ingesting excessive amounts of fluoride, typically through contaminated water or industrial exposure.
Patient care procedures performed during the operation that are ancillary to the actual surgery. It includes monitoring, fluid therapy, medication, transfusion, anesthesia, radiography, and laboratory tests.
Presence of calcium salts, especially calcium pyrophosphate, in the cartilaginous structures of one or more joints. When accompanied by attacks of goutlike symptoms, it is called pseudogout. (Dorland, 27th ed)
The bones of the free part of the upper extremity including the HUMERUS; RADIUS; and ULNA.
A syndrome that is characterized by the triad of severe PEPTIC ULCER, hypersecretion of GASTRIC ACID, and GASTRIN-producing tumors of the PANCREAS or other tissue (GASTRINOMA). This syndrome may be sporadic or be associated with MULTIPLE ENDOCRINE NEOPLASIA TYPE 1.
The largest of three bones that make up each half of the pelvic girdle.
Conditions in which the KIDNEYS perform below the normal level for more than three months. Chronic kidney insufficiency is classified by five stages according to the decline in GLOMERULAR FILTRATION RATE and the degree of kidney damage (as measured by the level of PROTEINURIA). The most severe form is the end-stage renal disease (CHRONIC KIDNEY FAILURE). (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002)
Formation of stones in the KIDNEY.
Agents that inhibit BONE RESORPTION and/or favor BONE MINERALIZATION and BONE REGENERATION. They are used to heal BONE FRACTURES and to treat METABOLIC BONE DISEASES such as OSTEOPOROSIS.
Vitamin K-dependent calcium-binding protein synthesized by OSTEOBLASTS and found primarily in BONES. Serum osteocalcin measurements provide a noninvasive specific marker of bone metabolism. The protein contains three residues of the amino acid gamma-carboxyglutamic acid (Gla), which, in the presence of CALCIUM, promotes binding to HYDROXYAPATITE and subsequent accumulation in BONE MATRIX.
Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group.
An abnormal hardening or increased density of bone tissue.
A non-hereditary KIDNEY disorder characterized by the abnormally dilated (ECTASIA) medullary and inner papillary portions of the collecting ducts. These collecting ducts usually contain CYSTS or DIVERTICULA filled with jelly-like material or small calculi (KIDNEY STONES) leading to infections or obstruction. It should be distinguished from congenital or hereditary POLYCYSTIC KIDNEY DISEASES.
Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.
The constant checking on the state or condition of a patient during the course of a surgical operation (e.g., checking of vital signs).
The part of a human or animal body connecting the HEAD to the rest of the body.
Cholecalciferols substituted with two hydroxy groups in any position.
Native, inorganic or fossilized organic substances having a definite chemical composition and formed by inorganic reactions. They may occur as individual crystals or may be disseminated in some other mineral or rock. (Grant & Hackh's Chemical Dictionary, 5th ed; McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed)
Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.
Calcium compounds used as food supplements or in food to supply the body with calcium. Dietary calcium is needed during growth for bone development and for maintenance of skeletal integrity later in life to prevent osteoporosis.
A repeat operation for the same condition in the same patient due to disease progression or recurrence, or as followup to failed previous surgery.
Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, environmental exposure and its effects, disease diagnosis, metabolic processes, substance abuse, pregnancy, cell line development, epidemiologic studies, etc.
The co-occurrence of pregnancy and NEOPLASMS. The neoplastic disease may precede or follow FERTILIZATION.
Malignant neoplasm arising from the epithelium of the BRONCHI. It represents a large group of epithelial lung malignancies which can be divided into two clinical groups: SMALL CELL LUNG CANCER and NON-SMALL-CELL LUNG CARCINOMA.
Hypersecretion of THYROID HORMONES from the THYROID GLAND. Elevated levels of thyroid hormones increase BASAL METABOLIC RATE.
Organic substances that are required in small amounts for maintenance and growth, but which cannot be manufactured by the human body.
Disorders caused by interruption of BONE MINERALIZATION manifesting as OSTEOMALACIA in adults and characteristic deformities in infancy and childhood due to disturbances in normal BONE FORMATION. The mineralization process may be interrupted by disruption of VITAMIN D; PHOSPHORUS; or CALCIUM homeostasis, resulting from dietary deficiencies, or acquired, or inherited metabolic, or hormonal disturbances.
Injections introduced directly into localized lesions.
Any detectable and heritable alteration in the lineage of germ cells. Mutations in these cells (i.e., "generative" cells ancestral to the gametes) are transmitted to progeny while those in somatic cells are not.
Elements of limited time intervals, contributing to particular results or situations.
A gamma-emitting radionuclide imaging agent used primarily in skeletal scintigraphy. Because of its absorption by a variety of tumors, it is useful for the detection of neoplasms.
Classic quantitative assay for detection of antigen-antibody reactions using a radioactively labeled substance (radioligand) either directly or indirectly to measure the binding of the unlabeled substance to a specific antibody or other receptor system. Non-immunogenic substances (e.g., haptens) can be measured if coupled to larger carrier proteins (e.g., bovine gamma-globulin or human serum albumin) capable of inducing antibody formation.
Derivative of 7-dehydroxycholesterol formed by ULTRAVIOLET RAYS breaking of the C9-C10 bond. It differs from ERGOCALCIFEROL in having a single bond between C22 and C23 and lacking a methyl group at C24.
Synthetic thermoplastics that are tough, flexible, inert, and resistant to chemicals and electrical current. They are often used as biocompatible materials for prostheses and implants.
A benign tumor, usually found in the anterior lobe of the pituitary gland, whose cells stain with acid dyes. Such pituitary tumors may give rise to excessive secretion of growth hormone, resulting in gigantism or acromegaly. A specific type of acidophil adenoma may give rise to nonpuerperal galactorrhea. (Dorland, 27th ed)
Pathologic processes that affect patients after a surgical procedure. They may or may not be related to the disease for which the surgery was done, and they may or may not be direct results of the surgery.
The period during a surgical operation.
Reduction of bone mass without alteration in the composition of bone, leading to fractures. Primary osteoporosis can be of two major types: postmenopausal osteoporosis (OSTEOPOROSIS, POSTMENOPAUSAL) and age-related or senile osteoporosis.
A family of small polypeptide growth factors that share several common features including a strong affinity for HEPARIN, and a central barrel-shaped core region of 140 amino acids that is highly homologous between family members. Although originally studied as proteins that stimulate the growth of fibroblasts this distinction is no longer a requirement for membership in the fibroblast growth factor family.
The B-cell leukemia/lymphoma-1 genes, associated with various neoplasms when overexpressed. Overexpression results from the t(11;14) translocation, which is characteristic of mantle zone-derived B-cell lymphomas. The human c-bcl-1 gene is located at 11q13 on the long arm of chromosome 11.
Benign hypertrophy that projects outward from the surface of bone, often containing a cartilaginous component.
Excision of kidney.
Combination or superimposition of two images for demonstrating differences between them (e.g., radiograph with contrast vs. one without, radionuclide images using different radionuclides, radiograph vs. radionuclide image) and in the preparation of audiovisual materials (e.g., offsetting identical images, coloring of vessels in angiograms).

Brown tumor of the mandible as first manifestation of primary hyperparathyroidism: diagnosis and treatment. (1/246)

Brown tumor is one of the lesions that develop in patients with hyperparathyroidism. Any of the skeletal bones can be affected including the cranio-maxillofacial ones. Most of the times the brown tumor appears after a final diagnosis of hyperparathyroidism is made. However brown tumor can be the first clinical sign of the disease. A clinical case in which a brown tumor located in the anterior part of the mandible appears as the first sign of primary hyperparathyroidism is presented. The possible differential clinical diagnosis and the recommended treatments are revised.  (+info)

Utilisation of a cryptic non-canonical donor splice site of the gene encoding PARAFIBROMIN is associated with familial isolated primary hyperparathyroidism. (2/246)

More than 99% of all splice sites conform to consensus sequences that usually include the invariant dinucleotides gt and ag at the 5' and 3' ends of the introns, respectively. We report on the utilisation of a non-consensus (non-canonical) donor splice site within exon 1 of the HRPT2 gene in familial isolated primary hyperparathyroidism (FIHP). HRPT2 mutations are more frequently associated with the hyperparathyroidism-jaw tumour syndrome (HPT-JT). Patients with FIHP were identified to have a donor splice site mutation, IVS1+1 g-->a, and the consequences of this for RNA processing were investigated. The mutant mRNA lacked 30 bp and DNA sequence analysis revealed this to result from utilisation of an alternative cryptic non-canonical donor splice site (gaatgt) in exon 1 together with the normally occurring acceptor splice site in intron 1. Translation of this mutant mRNA predicted the in-frame loss of 10 amino acids in the encoded protein, termed PARAFIBROMIN. Thus, these FIHP patients are utilising a ga-ag splice site pair, which until recently was considered to be incompatible with splicing but is now known to occur as a rare (<0.02%) normal splicing variant.  (+info)

Changes in clinical and laboratory findings at the time of diagnosis of primary hyperparathyroidism in a University Hospital in Sao Paulo from 1985 to 2002. (3/246)

In contrast to most developed countries, most patients with primary hyperparathyroidism in Brazil are still symptomatic at diagnosis. However, we have been observing a change in this pattern, especially in the last few years. We evaluated 104 patients, 77 females and 27 males aged 11-79 years (mean: 54.4 years), diagnosed between 1985 and 2002 at a University Hospital. Diagnosis was made on the basis of clinical findings and of high total and/or ionized calcium levels, high or inappropriate levels of intact parathyroid hormone and of surgical findings in 80 patients. Patients were divided into three groups, i.e., patients diagnosed from 1985 to 1989, patients diagnosed from 1990 to 1994, and patients diagnosed from 1995 to 2002. The number of new cases diagnosed/year increased from 1.8/year in the first group to 6.0/year in the second group and 8.1/year in the third group. The first group comprised 9 patients (mean serum calcium +/- SD, 13.6 +/- 1.6 mg/dl), 8 of them (88.8%) defined as symptomatic. The second group comprised 30 patients (mean calcium +/- SD, 12.2 +/- 1.63 mg/dl), 22 of them defined as symptomatic (73.3%). The third group contained 65 patients (mean calcium 11.7 +/- 1.1 mg/dl), 34 of them symptomatic (52.3%). Patients from the first group tended to be younger (mean +/- SD, 43.0 +/- 15 vs 55.1 +/- 14.4 and 55.7 +/- 17.3 years, respectively) and their mean serum calcium was significantly higher (P < 0.05). All of symptomatic patients independent of group had higher serum calcium levels (12.4 +/- 1.53 mg/dl, N = 64) than asymptomatic patients (11.4 +/- 1.0 mg/dl, N = 40). Our data showed an increase in the percentage of asymptomatic patients over the years in the number of primary hyperparathyroidism cases diagnosed. This finding may be due to an increased availability of diagnostic methods and/or to an increased awareness about the disease.  (+info)

Analysis of 645 patients with primary hyperparathyroidism with special references to cholelithiasis. (4/246)

OBJECTIVE The clinical picture of primary hyperparathyroidism (PHPT) has changed during the past 50 years. It is currently unknown whether or not PHPT is associated with an increased risk of cholelithiasis. PATIENTS: To determine the frequency of cholelithiasis in PHPT we analyzed 645 consecutive patients seen at Prague University Hospital from 1992 through 2002 and compared them with a of normocalcaemic control group. METHODS: We investigated 645 patients with proven PHPT (518 female and 127 males aged 20-80 years) during a period of 10 years. To determine the frequency of cholelithiasis in normal population we analyzed 2,015 patients receiving periodic health examination at an outpatient ward from January 1998 to December 1998 (1505 females and 510 males aged 24-85 years). A detailed history, physical examination, biochemical measurements and abdominal ultrasonography were done. RESULTS: Cholelithiasis was proven in 157 of 518 women (30.3%) and in 11 of 127 men (8.66%) with PHPT. Their mean age was 59.67+/-12 years in women and 56.0+/-10 years in men. In the control group 260 of 1505 women (17.27%) and 54 of the 510 men (10.58%) had cholelithiasis. The mean age was 64.55+/-13.8 years in women and 61.2+/-12.4 in men. Only in the case of women, the difference was highly statistically significant (p<0.001). There were no significant differences between the mean values for the serum calcium level, bone alkaline phosphatase, total cholesterol, urinary hydroxyproline and body mass index in hyperparathyroid patients with and without cholelithiasis. However the hyperparathyroid women with cholelithiasis had an increased concentration of parathyroid hormone (236.1+/-56 pg/ml) compared with hyperparathyroid women without cholelithiasis (179.0+/-45 pg/ml), p<0.01. CONCLUSION: The mechanism of PTH associated gallstone formation may involve inhibition of gallblader emptying, hepatic bile secretion and sphincter Oddi motility as well as modification of bile composition. While it might be difficult to prove it seems likely that the association of cholelithiasis with primary hyperparathyroidism in women with a high concentration of parathyroid hormone is more than merely coincidental and from our study it is obvious that a significant association exists.  (+info)

Surgery versus medical follow-up in patients with asymptomatic primary hyperparathyroidism: a decision analysis. (5/246)

OBJECTIVES: To examine the cost-effectiveness of strategies for management of primary asymptomatic hyperparathyroidism: surgical strategies and medical follow-up versus surgery. DESIGN: We used a Markov state-transition decision-analytic model for an hypothetical cohort of 55-year-old women to compare with a lifetime horizon costs and effectiveness of bilateral neck exploration (BNE), unilateral neck exploration (UNE), video-assisted parathyroidectomy (VAP) and lifelong medical follow-up shifting for either BNE or UNE in case of disease progression. METHODS: Data on localization tests, complications and treatment efficacies were derived from a systematic review of the literature. Outcomes were expressed as quality-adjusted life years (QALY). Costs (2002 Euro) discounted at 3% yearly were estimated from the health care system perspective. RESULTS: In the base-case analysis, VAP strategy (VAPS) was the most effective and BNE strategy (BNES) was the least costly. UNE strategy (UNES) had an incremental cost-effectiveness ratio of 2688 Euro/QALY versus BNES and VAPS of 17,250 Euro/QALY in comparison with UNES. Surgical management was more effective than medical follow-up with acceptable incremental cost-effectiveness ratios. VAPS became less effective than UNES over 71 years. Differences between UNES and VAPS were sensitive to success and complication rates, quality-of-life weights and procedural costs. Medical follow-up strategies became the most effective if quality-of-life weight for this condition was higher than 0.99. CONCLUSIONS: Surgery is more effective than medical follow-up at a reasonable cost and can be preferred except in patients choosing medical follow-up. Minimally invasive surgery is cost-effective compared to the traditional surgical approach.  (+info)

Regulation of plasma fibroblast growth factor 23 by calcium in primary hyperparathyroidism. (6/246)

OBJECTIVE: While the importance of fibroblast growth factor (FGF)-23 is established in phosphate-wasting disorders, little is known about the mechanisms regulating its circulating level. To investigate the role of parathyroid hormone (PTH) and calcium in FGF-23 metabolism, we examined plasma FGF-23 levels in patients with primary hyperparathyroidism (PHPT). PATIENTS AND METHODS: Fifty patients with PHPT and 52 controls were employed in this study. Plasma was obtained from 18 PHPT patients who underwent parathyroidectomy (PTX) on the first postoperative morning without vitamin D administration. Time-course samples were also obtained from 5 of 18 PTX patients without vitamin D analogs or calcium administration. The expression of Fgf23 on resected parathyroid glands was analyzed by reverse transcription (RT)-PCR and immunohistochemistry. RESULTS: FGF-23 was significantly elevated in PHPT patients compared with controls. FGF-23 levels were significantly correlated positively with serum corrected calcium and intact PTH levels, and negatively with creatinine clearance and inorganic phosphate, among which creatinine clearance and corrected calcium were independently associated factors. In 18 PTX patients, postoperative FGF-23 levels were significantly decreased compared with preoperative levels. Corrected-calcium levels were significantly decreased 1 h after PTX, and this was followed by a reduction in plasma FGF-23 levels in time-course study. In addition, postoperative FGF-23 levels in 18 PTX patients were significantly correlated with corrected calcium, consistent with a role of serum calcium as one of the major regulators of FGF-23. The absence of Fgf23 expression in parathyroid glands indicated that the parathyroid glands were not major sources of circulating FGF-23. CONCLUSIONS: Serum calcium may regulate circulating FGF-23 levels in PHPT.  (+info)

Unexpected serum parathyroid hormone profiles in some patients with primary hyperparathyroidism. (7/246)

BACKGROUND: Third-generation parathyroid hormone (PTH) assays have been reported to measure only intact PTH(1-84), in contrast to second-generation assays, which also detect PTH(7-84) fragments. Higher PTH measurements were observed with third- than with second-generation PTH assays in a few patients with either severe primary hyperparathyroidism or parathyroid carcinoma. METHODS: We analyzed biological data [second- and third-generation PTH assays, 25-hydroxyvitamin D (25-OHD), calcium, and phosphate concentrations] obtained before and after surgery for 2 groups of patients selected from a large series of consecutive patients with primary hyperparathyroidism (PHPT): 7 female patients with surgically and histologically confirmed PHPT (group 1) and a matched group (group 2). RESULTS: For group 1 but not group 2, PTH concentrations measured by third-generation PTH assays before surgery were higher than those measured by the second-generation assays. Circulating 25-OHD, calcium, and phosphate concentrations were similar in both groups. In addition, PTH values measured with the third-generation PTH assays in group 1 decreased after surgery. CONCLUSIONS: Our results confirm that third-generation PTH assays do not measure only PTH(1-84). The frequency of this unexpected finding of markedly lower PTH concentrations than previously reported was approximately 5% in patients with PHPT without malignancy. We do not know whether the presence of this unexpected profile is predictive of malignancy.  (+info)

A case of adrenocorticotropin-independent bilateral adrenal macronodular hyperplasia (AIMAH) with primary hyperparathyroidism (PHPT). (8/246)

We report a rare case of ACTH-independent macronodular adrenal hyperplasia (AIMAH) with primary hyperparathyroidism (PHPT). A 57-year-old woman was admitted to our hospital for further examination of secondary hypertension and bilateral adrenal macrotumors. Midnight serum cortisol elevation with undetectable plasma ACTH, increased 24-hour urinary free cortisol excretion, and loss of the normal circadian rhythm in cortisol secretion established the diagnosis of Cushing's syndrome. Total resection of the enlarged left adrenal gland was performed with subsequent steroid replacement. Her general condition improved but serum calcium level increased 3 weeks after surgery. PHPT was diagnosed on the basis of endocrinological examination, although imaging studies failed to detect parathyroid lesion. In summary, we believe this to be the first report of a case of AIMAH with PHPT.  (+info)

Hyperparathyroidism is a condition in which the parathyroid glands produce excessive amounts of parathyroid hormone (PTH). There are four small parathyroid glands located in the neck, near or within the thyroid gland. They release PTH into the bloodstream to help regulate the levels of calcium and phosphorus in the body.

In hyperparathyroidism, overproduction of PTH can lead to an imbalance in these minerals, causing high blood calcium levels (hypercalcemia) and low phosphate levels (hypophosphatemia). This can result in various symptoms such as fatigue, weakness, bone pain, kidney stones, and cognitive issues.

There are two types of hyperparathyroidism: primary and secondary. Primary hyperparathyroidism occurs when there is a problem with one or more of the parathyroid glands, causing them to become overactive and produce too much PTH. Secondary hyperparathyroidism develops as a response to low calcium levels in the body due to conditions like vitamin D deficiency, chronic kidney disease, or malabsorption syndromes.

Treatment for hyperparathyroidism depends on the underlying cause and severity of symptoms. In primary hyperparathyroidism, surgery to remove the overactive parathyroid gland(s) is often recommended. For secondary hyperparathyroidism, treating the underlying condition and managing calcium levels with medications or dietary changes may be sufficient.

Primary hyperparathyroidism is a medical condition characterized by excessive secretion of parathyroid hormone (PTH) from one or more of the parathyroid glands in the neck. These glands are normally responsible for regulating calcium levels in the body by releasing PTH, which helps to maintain an appropriate balance of calcium and phosphate in the bloodstream.

In primary hyperparathyroidism, the parathyroid gland(s) become overactive and produce too much PTH, leading to elevated calcium levels (hypercalcemia) in the blood. This can result in a variety of symptoms, such as fatigue, weakness, bone pain, kidney stones, and cognitive impairment, although some individuals may not experience any symptoms at all.

The most common cause of primary hyperparathyroidism is a benign tumor called an adenoma that develops in one or more of the parathyroid glands. In rare cases, primary hyperparathyroidism can be caused by cancer of the parathyroid gland(s) or by enlargement of all four glands (four-gland hyperplasia). Treatment typically involves surgical removal of the affected parathyroid gland(s), which is usually curative.

Secondary hyperparathyroidism is a condition characterized by an overproduction of parathyroid hormone (PTH) from the parathyroid glands due to hypocalcemia (low levels of calcium in the blood). This condition is usually a result of chronic kidney disease, where the kidneys fail to convert vitamin D into its active form, leading to decreased absorption of calcium in the intestines. The body responds by increasing PTH production to maintain normal calcium levels, but over time, this results in high PTH levels and associated complications such as bone disease, kidney stones, and cardiovascular calcification.

Parathyroidectomy is a surgical procedure for the removal of one or more of the parathyroid glands. These glands are located in the neck and are responsible for producing parathyroid hormone (PTH), which helps regulate the levels of calcium and phosphorus in the body.

Parathyroidectomy is typically performed to treat conditions such as hyperparathyroidism, where one or more of the parathyroid glands become overactive and produce too much PTH. This can lead to high levels of calcium in the blood, which can cause symptoms such as weakness, fatigue, bone pain, kidney stones, and mental confusion.

There are different types of parathyroidectomy procedures, including:

* Partial parathyroidectomy: removal of one or more, but not all, of the parathyroid glands.
* Total parathyroidectomy: removal of all four parathyroid glands.
* Subtotal parathyroidectomy: removal of three and a half of the four parathyroid glands, leaving a small portion of one gland to prevent hypoparathyroidism (a condition where the body produces too little PTH).

The choice of procedure depends on the underlying condition and its severity. After the surgery, patients may need to have their calcium levels monitored and may require calcium and vitamin D supplements to maintain normal calcium levels in the blood.

Parathyroid neoplasms refer to abnormal growths in the parathyroid glands, which are small endocrine glands located in the neck, near or within the thyroid gland. These neoplasms can be benign (non-cancerous) or malignant (cancerous).

Benign parathyroid neoplasms are typically called parathyroid adenomas and are the most common type of parathyroid disorder. They result in overproduction of parathyroid hormone (PTH), leading to a condition known as primary hyperparathyroidism. Symptoms may include kidney stones, osteoporosis, fatigue, depression, and abdominal pain.

Malignant parathyroid neoplasms are called parathyroid carcinomas. They are rare but more aggressive than adenomas, with a higher risk of recurrence and metastasis. Symptoms are similar to those of benign neoplasms but may also include hoarseness, difficulty swallowing, and enlarged lymph nodes in the neck.

It is important to note that parathyroid neoplasms can only be definitively diagnosed through biopsy or surgical removal and subsequent histopathological examination.

The parathyroid glands are four small endocrine glands located in the neck, usually near or behind the thyroid gland. They secrete parathyroid hormone (PTH), which plays a critical role in regulating calcium and phosphate levels in the blood and bones. PTH helps maintain the balance of these minerals by increasing the absorption of calcium from food in the intestines, promoting reabsorption of calcium in the kidneys, and stimulating the release of calcium from bones when needed. Additionally, PTH decreases the excretion of calcium through urine and reduces phosphate reabsorption in the kidneys, leading to increased phosphate excretion. Disorders of the parathyroid glands can result in conditions such as hyperparathyroidism (overactive glands) or hypoparathyroidism (underactive glands), which can have significant impacts on calcium and phosphate homeostasis and overall health.

Parathyroid hormone (PTH) is a polypeptide hormone that plays a crucial role in the regulation of calcium and phosphate levels in the body. It is produced and secreted by the parathyroid glands, which are four small endocrine glands located on the back surface of the thyroid gland.

The primary function of PTH is to maintain normal calcium levels in the blood by increasing calcium absorption from the gut, mobilizing calcium from bones, and decreasing calcium excretion by the kidneys. PTH also increases phosphate excretion by the kidneys, which helps to lower serum phosphate levels.

In addition to its role in calcium and phosphate homeostasis, PTH has been shown to have anabolic effects on bone tissue, stimulating bone formation and preventing bone loss. However, chronic elevations in PTH levels can lead to excessive bone resorption and osteoporosis.

Overall, Parathyroid Hormone is a critical hormone that helps maintain mineral homeostasis and supports healthy bone metabolism.

Hypercalcemia is a medical condition characterized by an excess of calcium ( Ca2+ ) in the blood. While the normal range for serum calcium levels is typically between 8.5 to 10.2 mg/dL (milligrams per deciliter) or 2.14 to 2.55 mmol/L (millimoles per liter), hypercalcemia is generally defined as a serum calcium level greater than 10.5 mg/dL or 2.6 mmol/L.

Hypercalcemia can result from various underlying medical disorders, including primary hyperparathyroidism, malignancy (cancer), certain medications, granulomatous diseases, and excessive vitamin D intake or production. Symptoms of hypercalcemia may include fatigue, weakness, confusion, memory loss, depression, constipation, nausea, vomiting, increased thirst, frequent urination, bone pain, and kidney stones. Severe or prolonged hypercalcemia can lead to serious complications such as kidney failure, cardiac arrhythmias, and calcification of soft tissues. Treatment depends on the underlying cause and severity of the condition.

Osteitis fibrosa cystica is a medical condition that refers to the abnormal bone remodeling process characterized by increased bone resorption and formation, leading to bone thickening and weakening. It is also known as "von Recklinghausen's disease of bone" or "monostotic fibrous dysplasia."

This condition is typically caused by excessive production of parathyroid hormone (PTH) due to a benign or malignant tumor of the parathyroid gland, known as hyperparathyroidism. The overproduction of PTH leads to an imbalance in calcium and phosphorus metabolism, resulting in increased bone resorption and fibrous tissue deposition within the bone marrow.

The clinical features of osteitis fibrosa cystica include bone pain, fractures, bone deformities, and elevated levels of calcium and alkaline phosphatase in the blood. Radiographic findings may show characteristic "rugger jersey" or "salt and pepper" patterns of alternating areas of increased and decreased bone density.

Treatment typically involves surgical removal of the abnormal parathyroid gland tissue, followed by medical management to prevent further bone loss and promote healing.

An adenoma is a benign (noncancerous) tumor that develops from glandular epithelial cells. These types of cells are responsible for producing and releasing fluids, such as hormones or digestive enzymes, into the surrounding tissues. Adenomas can occur in various organs and glands throughout the body, including the thyroid, pituitary, adrenal, and digestive systems.

Depending on their location, adenomas may cause different symptoms or remain asymptomatic. Some common examples of adenomas include:

1. Colorectal adenoma (also known as a polyp): These growths occur in the lining of the colon or rectum and can develop into colorectal cancer if left untreated. Regular screenings, such as colonoscopies, are essential for early detection and removal of these polyps.
2. Thyroid adenoma: This type of adenoma affects the thyroid gland and may result in an overproduction or underproduction of hormones, leading to conditions like hyperthyroidism (overactive thyroid) or hypothyroidism (underactive thyroid).
3. Pituitary adenoma: These growths occur in the pituitary gland, which is located at the base of the brain and controls various hormonal functions. Depending on their size and location, pituitary adenomas can cause vision problems, headaches, or hormonal imbalances that affect growth, reproduction, and metabolism.
4. Liver adenoma: These rare benign tumors develop in the liver and may not cause any symptoms unless they become large enough to press on surrounding organs or structures. In some cases, liver adenomas can rupture and cause internal bleeding.
5. Adrenal adenoma: These growths occur in the adrenal glands, which are located above the kidneys and produce hormones that regulate stress responses, metabolism, and blood pressure. Most adrenal adenomas are nonfunctioning, meaning they do not secrete excess hormones. However, functioning adrenal adenomas can lead to conditions like Cushing's syndrome or Conn's syndrome, depending on the type of hormone being overproduced.

It is essential to monitor and manage benign tumors like adenomas to prevent potential complications, such as rupture, bleeding, or hormonal imbalances. Treatment options may include surveillance with imaging studies, medication to manage hormonal issues, or surgical removal of the tumor in certain cases.

Calcimimetic agents are a type of medication that mimic the action of calcium on the calcium-sensing receptor (CaSR) in the parathyroid gland. These agents enhance the sensitivity of the CaSR to extracellular calcium, which leads to a decrease in parathyroid hormone (PTH) secretion.

Calcimimetics are primarily used in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease (CKD) on dialysis. By decreasing PTH levels, calcimimetics can help to prevent the development of bone disease, reduce the risk of cardiovascular calcification, and improve overall clinical outcomes in these patients.

The most commonly prescribed calcimimetic agent is cinacalcet (Sensipar/Mimpara), which has been shown to effectively lower PTH levels, as well as serum calcium and phosphorus levels, in patients with CKD on dialysis. Other calcimimetic agents include etelcalcetide (Parsabiv) and evocalcet (Rocaltrol).

It is important to note that calcimimetics should be used with caution in patients with hypocalcemia, as they can further lower serum calcium levels. Close monitoring of calcium, phosphorus, and PTH levels is necessary during treatment with these agents.

Parathyroid diseases refer to conditions that affect the parathyroid glands, which are small endocrine glands located in the neck, near or attached to the back surface of the thyroid gland. The primary function of the parathyroid glands is to produce and secrete parathyroid hormone (PTH), a crucial hormone that helps regulate calcium and phosphorus levels in the blood and bones.

There are four parathyroid glands, and they can develop various diseases, including:

1. Hyperparathyroidism: A condition where one or more parathyroid glands produce excessive amounts of PTH. This can lead to an imbalance in calcium and phosphorus levels, resulting in symptoms such as fatigue, weakness, bone pain, kidney stones, and increased risk of osteoporosis. Hyperparathyroidism can be primary (caused by a benign or malignant tumor in the parathyroid gland), secondary (due to chronic kidney disease or vitamin D deficiency), or tertiary (when secondary hyperparathyroidism becomes autonomous and continues even after correcting the underlying cause).
2. Hypoparathyroidism: A condition where the parathyroid glands do not produce enough PTH, leading to low calcium levels in the blood (hypocalcemia) and high phosphorus levels (hyperphosphatemia). Symptoms of hypoparathyroidism may include muscle spasms, tingling sensations in the fingers, toes, or lips, anxiety, cataracts, and seizures. Hypoparathyroidism can be caused by surgical removal of the parathyroid glands, autoimmune disorders, radiation therapy, or genetic conditions.
3. Parathyroid tumors: Abnormal growths in the parathyroid glands can lead to hyperparathyroidism. Benign tumors (adenomas) are the most common cause of primary hyperparathyroidism. Malignant tumors (carcinomas) are rare but can also occur, leading to more severe symptoms and a worse prognosis.
4. Parathyroid dysfunction in genetic disorders: Some genetic syndromes, such as multiple endocrine neoplasia type 1 (MEN1), multiple endocrine neoplasia type 2A (MEN2A), and hyperparathyroidism-jaw tumor syndrome (HPT-JT), can involve parathyroid gland abnormalities, leading to hyperparathyroidism or other related conditions.

Proper diagnosis and management of parathyroid disorders are crucial for maintaining optimal calcium homeostasis and preventing complications associated with hypocalcemia or hypercalcemia. Treatment options may include surgery, medication, dietary modifications, and monitoring hormone levels.

Hypocalcemia is a medical condition characterized by an abnormally low level of calcium in the blood. Calcium is a vital mineral that plays a crucial role in various bodily functions, including muscle contraction, nerve impulse transmission, and bone formation. Normal calcium levels in the blood usually range from 8.5 to 10.2 milligrams per deciliter (mg/dL). Hypocalcemia is typically defined as a serum calcium level below 8.5 mg/dL or, when adjusted for albumin (a protein that binds to calcium), below 8.4 mg/dL (ionized calcium).

Hypocalcemia can result from several factors, such as vitamin D deficiency, hypoparathyroidism (underactive parathyroid glands), kidney dysfunction, certain medications, and severe magnesium deficiency. Symptoms of hypocalcemia may include numbness or tingling in the fingers, toes, or lips; muscle cramps or spasms; seizures; and, in severe cases, cognitive impairment or cardiac arrhythmias. Treatment typically involves correcting the underlying cause and administering calcium and vitamin D supplements to restore normal calcium levels in the blood.

Calcium-sensing receptors (CaSR) are a type of G protein-coupled receptor that play a crucial role in the regulation of extracellular calcium homeostasis. They are widely expressed in various tissues, including the parathyroid gland, kidney, and bone.

The primary function of CaSR is to detect changes in extracellular calcium concentrations and transmit signals to regulate the release of parathyroid hormone (PTH) from the parathyroid gland. When the concentration of extracellular calcium increases, CaSR is activated, which leads to a decrease in PTH secretion, thereby preventing further elevation of calcium levels. Conversely, when calcium levels decrease, CaSR is inhibited, leading to an increase in PTH release and restoration of normal calcium levels.

In addition to regulating calcium homeostasis, CaSR also plays a role in other physiological processes, including cell proliferation, differentiation, and apoptosis. Dysregulation of CaSR has been implicated in various diseases, such as hyperparathyroidism, hypoparathyroidism, and cancer. Therefore, understanding the function and regulation of CaSR is essential for developing new therapeutic strategies to treat these conditions.

Phosphorus is an essential mineral that is required by every cell in the body for normal functioning. It is a key component of several important biomolecules, including adenosine triphosphate (ATP), which is the primary source of energy for cells, and deoxyribonucleic acid (DNA) and ribonucleic acid (RNA), which are the genetic materials in cells.

Phosphorus is also a major constituent of bones and teeth, where it combines with calcium to provide strength and structure. In addition, phosphorus plays a critical role in various metabolic processes, including energy production, nerve impulse transmission, and pH regulation.

The medical definition of phosphorus refers to the chemical element with the atomic number 15 and the symbol P. It is a highly reactive non-metal that exists in several forms, including white phosphorus, red phosphorus, and black phosphorus. In the body, phosphorus is primarily found in the form of organic compounds, such as phospholipids, phosphoproteins, and nucleic acids.

Abnormal levels of phosphorus in the body can lead to various health problems. For example, high levels of phosphorus (hyperphosphatemia) can occur in patients with kidney disease or those who consume large amounts of phosphorus-rich foods, and can contribute to the development of calcification of soft tissues and cardiovascular disease. On the other hand, low levels of phosphorus (hypophosphatemia) can occur in patients with malnutrition, vitamin D deficiency, or alcoholism, and can lead to muscle weakness, bone pain, and an increased risk of infection.

Naphthalene is not typically referred to as a medical term, but it is a chemical compound with the formula C10H8. It is a white crystalline solid that is aromatic and volatile, and it is known for its distinctive mothball smell. In a medical context, naphthalene is primarily relevant as a potential toxin or irritant.

Naphthalene can be found in some chemical products, such as mothballs and toilet deodorant blocks. Exposure to high levels of naphthalene can cause symptoms such as nausea, vomiting, diarrhea, and headaches. Long-term exposure has been linked to anemia and damage to the liver and nervous system.

In addition, naphthalene is a known environmental pollutant that can be found in air, water, and soil. It is produced by the combustion of fossil fuels and is also released from some industrial processes. Naphthalene has been shown to have toxic effects on aquatic life and may pose a risk to human health if exposure levels are high enough.

Renal osteodystrophy is a bone disease that occurs in individuals with chronic kidney disease (CKD). It is characterized by abnormalities in the bones' structure and mineral composition due to disturbances in the metabolism of calcium, phosphorus, and vitamin D. These metabolic disturbances result from the kidneys' decreased ability to maintain balance in the levels of these minerals and hormones.

Renal osteodystrophy can manifest as several bone disorders, including:

1. Osteitis fibrosa cystica: Increased bone turnover due to excessive parathyroid hormone (PTH) production, leading to high levels of alkaline phosphatase and increased resorption of bones.
2. Adynamic bone disease: Decreased bone turnover due to reduced PTH levels, resulting in low bone formation rates and increased fracture risk.
3. Mixed uremic osteodystrophy: A combination of high and low bone turnover, with varying degrees of mineralization defects.
4. Osteomalacia: Defective mineralization of bones due to vitamin D deficiency or resistance, leading to soft and weak bones.

Symptoms of renal osteodystrophy may include bone pain, muscle weakness, fractures, deformities, and growth retardation in children. Diagnosis typically involves laboratory tests, imaging studies, and sometimes bone biopsies. Treatment focuses on correcting the metabolic imbalances through dietary modifications, medications (such as phosphate binders, vitamin D analogs, and calcimimetics), and addressing any secondary hyperparathyroidism if present.

Multiple Endocrine Neoplasia Type 1 (MEN1) is a rare inherited disorder characterized by the development of tumors in various endocrine glands. These tumors can be benign or malignant and may lead to overproduction of hormones, causing a variety of symptoms. The three main endocrine glands affected in MEN1 are:

1. Parathyroid glands: Over 90% of individuals with MEN1 develop multiple parathyroid tumors (parathyroid hyperplasia), leading to primary hyperparathyroidism, which results in high levels of calcium in the blood.
2. Pancreas: Up to 80% of individuals with MEN1 develop pancreatic neuroendocrine tumors (PNETs). These tumors can produce and release various hormones, such as gastrin, insulin, glucagon, and vasoactive intestinal peptide (VIP), leading to specific clinical syndromes like Zollinger-Ellison syndrome, hypoglycemia, or watery diarrhea.
3. Pituitary gland: Approximately 30-40% of individuals with MEN1 develop pituitary tumors, most commonly prolactinomas, which can cause menstrual irregularities, galactorrhea (milk production), and visual field defects.

MEN1 is caused by mutations in the MEN1 gene, located on chromosome 11, and it is inherited in an autosomal dominant manner. This means that a person has a 50% chance of inheriting the disease-causing mutation from an affected parent. The diagnosis of MEN1 typically requires meeting specific clinical criteria or having a positive genetic test for a pathogenic MEN1 gene variant. Regular monitoring and early intervention are crucial in managing this condition to prevent complications and improve outcomes.

Calcium is an essential mineral that is vital for various physiological processes in the human body. The medical definition of calcium is as follows:

Calcium (Ca2+) is a crucial cation and the most abundant mineral in the human body, with approximately 99% of it found in bones and teeth. It plays a vital role in maintaining structural integrity, nerve impulse transmission, muscle contraction, hormonal secretion, blood coagulation, and enzyme activation.

Calcium homeostasis is tightly regulated through the interplay of several hormones, including parathyroid hormone (PTH), calcitonin, and vitamin D. Dietary calcium intake, absorption, and excretion are also critical factors in maintaining optimal calcium levels in the body.

Hypocalcemia refers to low serum calcium levels, while hypercalcemia indicates high serum calcium levels. Both conditions can have detrimental effects on various organ systems and require medical intervention to correct.

Technetium Tc 99m Sestamibi is a radiopharmaceutical compound used in medical imaging, specifically in myocardial perfusion scintigraphy. It is a technetium-labeled isonitrile chelate that is taken up by mitochondria in cells with high metabolic activity, such as cardiomyocytes (heart muscle cells).

Once injected into the patient's body, Technetium Tc 99m Sestamibi emits gamma rays, which can be detected by a gamma camera. This allows for the creation of images that reflect the distribution and function of the radiopharmaceutical within the heart muscle. The images can help identify areas of reduced blood flow or ischemia, which may indicate coronary artery disease.

The uptake of Technetium Tc 99m Sestamibi in other organs, such as the breast and thyroid, can also be used for imaging purposes, although its primary use remains in cardiac imaging.

Chronic kidney failure, also known as chronic kidney disease (CKD) stage 5 or end-stage renal disease (ESRD), is a permanent loss of kidney function that occurs gradually over a period of months to years. It is defined as a glomerular filtration rate (GFR) of less than 15 ml/min, which means the kidneys are filtering waste and excess fluids at less than 15% of their normal capacity.

CKD can be caused by various underlying conditions such as diabetes, hypertension, glomerulonephritis, polycystic kidney disease, and recurrent kidney infections. Over time, the damage to the kidneys can lead to a buildup of waste products and fluids in the body, which can cause a range of symptoms including fatigue, weakness, shortness of breath, nausea, vomiting, and confusion.

Treatment for chronic kidney failure typically involves managing the underlying condition, making lifestyle changes such as following a healthy diet, and receiving supportive care such as dialysis or a kidney transplant to replace lost kidney function.

Ergocalciferols are a form of vitamin D, specifically vitamin D2, that is found in some plants. They are not produced by the human body and must be obtained through diet or supplementation. Ergocalciferols can be converted into an active form of vitamin D in the body, which is important for maintaining healthy bones and calcium levels. However, vitamin D3 (cholecalciferol), which is produced by the body in response to sunlight exposure, is generally considered to be more effective at raising and maintaining vitamin D levels in the body than ergocalciferols.

Calcitriol is the active form of vitamin D, also known as 1,25-dihydroxyvitamin D. It is a steroid hormone that plays a crucial role in regulating calcium and phosphate levels in the body to maintain healthy bones. Calcitriol is produced in the kidneys from its precursor, calcidiol (25-hydroxyvitamin D), which is derived from dietary sources or synthesized in the skin upon exposure to sunlight.

Calcitriol promotes calcium absorption in the intestines, helps regulate calcium and phosphate levels in the kidneys, and stimulates bone cells (osteoblasts) to form new bone tissue while inhibiting the activity of osteoclasts, which resorb bone. This hormone is essential for normal bone mineralization and growth, as well as for preventing hypocalcemia (low calcium levels).

In addition to its role in bone health, calcitriol has various other physiological functions, including modulating immune responses, cell proliferation, differentiation, and apoptosis. Calcitriol deficiency or resistance can lead to conditions such as rickets in children and osteomalacia or osteoporosis in adults.

Phosphates, in a medical context, refer to the salts or esters of phosphoric acid. Phosphates play crucial roles in various biological processes within the human body. They are essential components of bones and teeth, where they combine with calcium to form hydroxyapatite crystals. Phosphates also participate in energy transfer reactions as phosphate groups attached to adenosine diphosphate (ADP) and adenosine triphosphate (ATP). Additionally, they contribute to buffer systems that help maintain normal pH levels in the body.

Abnormal levels of phosphates in the blood can indicate certain medical conditions. High phosphate levels (hyperphosphatemia) may be associated with kidney dysfunction, hyperparathyroidism, or excessive intake of phosphate-containing products. Low phosphate levels (hypophosphatemia) might result from malnutrition, vitamin D deficiency, or certain diseases affecting the small intestine or kidneys. Both hypophosphatemia and hyperphosphatemia can have significant impacts on various organ systems and may require medical intervention.

Uremia is not a disease itself, but rather it's a condition that results from the buildup of waste products in the blood due to kidney failure. The term "uremia" comes from the word "urea," which is one of the waste products that accumulate when the kidneys are not functioning properly.

In uremia, the kidneys are unable to effectively filter waste and excess fluids from the blood, leading to a variety of symptoms such as nausea, vomiting, fatigue, itching, mental confusion, and ultimately, if left untreated, can lead to coma and death. It is a serious condition that requires immediate medical attention, often involving dialysis or a kidney transplant to manage the underlying kidney dysfunction.

Hyperplasia is a medical term that refers to an abnormal increase in the number of cells in an organ or tissue, leading to an enlargement of the affected area. It's a response to various stimuli such as hormones, chronic irritation, or inflammation. Hyperplasia can be physiological, like the growth of breast tissue during pregnancy, or pathological, like in the case of benign or malignant tumors. The process is generally reversible if the stimulus is removed. It's important to note that hyperplasia itself is not cancerous, but some forms of hyperplasia can increase the risk of developing cancer over time.

Hypoparathyroidism is a medical condition characterized by decreased levels or insufficient function of parathyroid hormone (PTH), which is produced and released by the parathyroid glands. These glands are located in the neck, near the thyroid gland, and play a crucial role in regulating calcium and phosphorus levels in the body.

In hypoparathyroidism, low PTH levels result in decreased absorption of calcium from the gut, increased excretion of calcium through the kidneys, and impaired regulation of bone metabolism. This leads to low serum calcium levels (hypocalcemia) and high serum phosphorus levels (hyperphosphatemia).

Symptoms of hypoparathyroidism can include muscle cramps, spasms, or tetany (involuntary muscle contractions), numbness or tingling sensations in the fingers, toes, and around the mouth, fatigue, weakness, anxiety, cognitive impairment, and in severe cases, seizures. Hypoparathyroidism can be caused by various factors, including surgical removal or damage to the parathyroid glands, autoimmune disorders, radiation therapy, genetic defects, or low magnesium levels. Treatment typically involves calcium and vitamin D supplementation to maintain normal serum calcium levels and alleviate symptoms. In some cases, recombinant PTH (Natpara) may be prescribed as well.

Renal dialysis is a medical procedure that is used to artificially remove waste products, toxins, and excess fluids from the blood when the kidneys are no longer able to perform these functions effectively. This process is also known as hemodialysis.

During renal dialysis, the patient's blood is circulated through a special machine called a dialyzer or an artificial kidney, which contains a semi-permeable membrane that filters out waste products and excess fluids from the blood. The cleaned blood is then returned to the patient's body.

Renal dialysis is typically recommended for patients with advanced kidney disease or kidney failure, such as those with end-stage renal disease (ESRD). It is a life-sustaining treatment that helps to maintain the balance of fluids and electrolytes in the body, prevent the buildup of waste products and toxins, and control blood pressure.

There are two main types of renal dialysis: hemodialysis and peritoneal dialysis. Hemodialysis is the most common type and involves using a dialyzer to filter the blood outside the body. Peritoneal dialysis, on the other hand, involves placing a catheter in the abdomen and using the lining of the abdomen (peritoneum) as a natural filter to remove waste products and excess fluids from the body.

Overall, renal dialysis is an essential treatment option for patients with kidney failure, helping them to maintain their quality of life and prolong their survival.

Vitamin D is a fat-soluble secosteroid that is crucial for the regulation of calcium and phosphate levels in the body, which are essential for maintaining healthy bones and teeth. It can be synthesized by the human body when skin is exposed to ultraviolet-B (UVB) rays from sunlight, or it can be obtained through dietary sources such as fatty fish, fortified dairy products, and supplements. There are two major forms of vitamin D: vitamin D2 (ergocalciferol), which is found in some plants and fungi, and vitamin D3 (cholecalciferol), which is produced in the skin or obtained from animal-derived foods. Both forms need to undergo two hydroxylations in the body to become biologically active as calcitriol (1,25-dihydroxyvitamin D3), the hormonally active form of vitamin D. This activated form exerts its effects by binding to the vitamin D receptor (VDR) found in various tissues, including the small intestine, bone, kidney, and immune cells, thereby influencing numerous physiological processes such as calcium homeostasis, bone metabolism, cell growth, and immune function.

Osteomalacia is a medical condition characterized by the softening of bones due to defective bone mineralization, resulting from inadequate vitamin D, phosphate, or calcium. It mainly affects adults and is different from rickets, which occurs in children. The primary symptom is bone pain, but muscle weakness can also occur. Prolonged osteomalacia may lead to skeletal deformities and an increased risk of fractures. Treatment typically involves supplementation with vitamin D, calcium, and sometimes phosphate.

Bone diseases is a broad term that refers to various medical conditions that affect the bones. These conditions can be categorized into several groups, including:

1. Developmental and congenital bone diseases: These are conditions that affect bone growth and development before or at birth. Examples include osteogenesis imperfecta (brittle bone disease), achondroplasia (dwarfism), and cleidocranial dysostosis.
2. Metabolic bone diseases: These are conditions that affect the body's ability to maintain healthy bones. They are often caused by hormonal imbalances, vitamin deficiencies, or problems with mineral metabolism. Examples include osteoporosis, osteomalacia, and Paget's disease of bone.
3. Inflammatory bone diseases: These are conditions that cause inflammation in the bones. They can be caused by infections, autoimmune disorders, or other medical conditions. Examples include osteomyelitis, rheumatoid arthritis, and ankylosing spondylitis.
4. Degenerative bone diseases: These are conditions that cause the bones to break down over time. They can be caused by aging, injury, or disease. Examples include osteoarthritis, avascular necrosis, and diffuse idiopathic skeletal hyperostosis (DISH).
5. Tumors and cancers of the bone: These are conditions that involve abnormal growths in the bones. They can be benign or malignant. Examples include osteosarcoma, chondrosarcoma, and Ewing sarcoma.
6. Fractures and injuries: While not strictly a "disease," fractures and injuries are common conditions that affect the bones. They can result from trauma, overuse, or weakened bones. Examples include stress fractures, compound fractures, and dislocations.

Overall, bone diseases can cause a wide range of symptoms, including pain, stiffness, deformity, and decreased mobility. Treatment for these conditions varies depending on the specific diagnosis but may include medication, surgery, physical therapy, or lifestyle changes.

Pathologic bone demineralization is a condition characterized by the loss of minerals, such as calcium and phosphate, from the bones. This process makes the bones more porous, weaker, and more susceptible to fractures. It can occur due to various medical conditions, including osteoporosis, hyperparathyroidism, Paget's disease of bone, and cancer that has spread to the bones (metastatic cancer).

In a healthy individual, the body constantly remodels the bones by removing old bone tissue (resorption) and replacing it with new tissue. This process is regulated by two types of cells: osteoclasts, which are responsible for bone resorption, and osteoblasts, which produce new bone tissue. In pathologic bone demineralization, there is an imbalance between the activity of these two cell types, with excessive resorption and inadequate formation of new bone tissue.

Pathologic bone demineralization can lead to a range of symptoms, including bone pain, fractures, loss of height, and a decreased ability to perform daily activities. Treatment for this condition depends on the underlying cause but may include medications that slow down bone resorption or promote bone formation, as well as lifestyle changes such as exercise and dietary modifications.

A choristoma is a type of growth that occurs when normally functioning tissue is found in an abnormal location within the body. It is not cancerous or harmful, but it can cause problems if it presses on surrounding structures or causes symptoms. Choristomas are typically congenital, meaning they are present at birth, and are thought to occur due to developmental errors during embryonic growth. They can be found in various organs and tissues throughout the body, including the brain, eye, skin, and gastrointestinal tract.

"Bone" is the hard, dense connective tissue that makes up the skeleton of vertebrate animals. It provides support and protection for the body's internal organs, and serves as a attachment site for muscles, tendons, and ligaments. Bone is composed of cells called osteoblasts and osteoclasts, which are responsible for bone formation and resorption, respectively, and an extracellular matrix made up of collagen fibers and mineral crystals.

Bones can be classified into two main types: compact bone and spongy bone. Compact bone is dense and hard, and makes up the outer layer of all bones and the shafts of long bones. Spongy bone is less dense and contains large spaces, and makes up the ends of long bones and the interior of flat and irregular bones.

The human body has 206 bones in total. They can be further classified into five categories based on their shape: long bones, short bones, flat bones, irregular bones, and sesamoid bones.

Paraneoplastic endocrine syndromes refer to a group of hormonal and related disorders that occur as remote effects of cancer. They are caused by substances (like hormones, peptides, or antibodies) produced by the tumor, which may be benign or malignant, and can affect various organs and systems in the body. These syndromes can occur before the cancer is diagnosed, making them an important consideration for early detection and treatment of the underlying malignancy.

Examples of paraneoplastic endocrine syndromes include:

1. Syndrome of Inappropriate Antidiuretic Hormone (SIADH): This occurs when a tumor, often small cell lung cancer, produces antidiuretic hormone (ADH), leading to excessive water retention and low sodium levels in the blood.
2. Cushing's Syndrome: Excessive production of adrenocorticotropic hormone (ACTH) by a tumor, often a small cell lung cancer or pancreatic neuroendocrine tumor, can lead to increased cortisol levels and symptoms such as weight gain, muscle weakness, and mood changes.
3. Ectopic Production of Parathyroid Hormone-Related Peptide (PTHrP): This occurs when a tumor, often a squamous cell carcinoma, produces PTHrP, leading to increased calcium levels in the blood and symptoms such as bone pain, kidney stones, and confusion.
4. Hypercalcemia of Malignancy: Excessive production of calcitriol (active vitamin D) by a tumor, often a lymphoma or myeloma, can lead to increased calcium levels in the blood and symptoms such as bone pain, kidney stones, and confusion.
5. Carcinoid Syndrome: This occurs when a neuroendocrine tumor, often in the gastrointestinal tract, produces serotonin and other substances, leading to symptoms such as flushing, diarrhea, and heart problems.

It is important to note that these syndromes can also be caused by non-cancerous conditions, so a thorough evaluation is necessary to make an accurate diagnosis.

Alkaline phosphatase (ALP) is an enzyme found in various body tissues, including the liver, bile ducts, digestive system, bones, and kidneys. It plays a role in breaking down proteins and minerals, such as phosphate, in the body.

The medical definition of alkaline phosphatase refers to its function as a hydrolase enzyme that removes phosphate groups from molecules at an alkaline pH level. In clinical settings, ALP is often measured through blood tests as a biomarker for various health conditions.

Elevated levels of ALP in the blood may indicate liver or bone diseases, such as hepatitis, cirrhosis, bone fractures, or cancer. Therefore, physicians may order an alkaline phosphatase test to help diagnose and monitor these conditions. However, it is essential to interpret ALP results in conjunction with other diagnostic tests and clinical findings for accurate diagnosis and treatment.

Hyperphosphatemia is a medical condition characterized by an excessively high level of phosphate (a form of the chemical element phosphorus) in the blood. Phosphate is an important component of various biological molecules, such as DNA, RNA, and ATP, and it plays a crucial role in many cellular processes, including energy metabolism and signal transduction.

In healthy individuals, the concentration of phosphate in the blood is tightly regulated within a narrow range to maintain normal physiological functions. However, when the phosphate level rises above this range (typically defined as a serum phosphate level greater than 4.5 mg/dL or 1.46 mmol/L), it can lead to hyperphosphatemia.

Hyperphosphatemia can result from various underlying medical conditions, including:

* Kidney dysfunction: The kidneys are responsible for filtering excess phosphate out of the blood and excreting it in the urine. When the kidneys fail to function properly, they may be unable to remove enough phosphate, leading to its accumulation in the blood.
* Hypoparathyroidism: The parathyroid glands produce a hormone called parathyroid hormone (PTH), which helps regulate calcium and phosphate levels in the body. In hypoparathyroidism, the production of PTH is insufficient, leading to an increase in phosphate levels.
* Hyperparathyroidism: In contrast, excessive production of PTH can also lead to hyperphosphatemia by increasing the release of phosphate from bones and decreasing its reabsorption in the kidneys.
* Excessive intake of phosphate-rich foods or supplements: Consuming large amounts of phosphate-rich foods, such as dairy products, nuts, and legumes, or taking phosphate supplements can raise blood phosphate levels.
* Tumor lysis syndrome: This is a complication that can occur after the treatment of certain types of cancer, particularly hematological malignancies. The rapid destruction of cancer cells releases large amounts of intracellular contents, including phosphate, into the bloodstream, leading to hyperphosphatemia.
* Rhabdomyolysis: This is a condition in which muscle tissue breaks down, releasing its contents, including phosphate, into the bloodstream. It can be caused by various factors, such as trauma, infection, or drug toxicity.

Hyperphosphatemia can have several adverse effects on the body, including calcification of soft tissues, kidney damage, and metabolic disturbances. Therefore, it is essential to diagnose and manage hyperphosphatemia promptly to prevent complications. Treatment options may include dietary modifications, medications that bind phosphate in the gastrointestinal tract, and dialysis in severe cases.

Calcium gluconate is a medical compound that is used primarily as a medication to treat conditions related to low calcium levels in the body (hypocalcemia) or to prevent calcium deficiency. It is also used as an antidote for treating poisoning from certain chemicals, such as beta-blockers and fluoride.

Calcium gluconate is a form of calcium salt, which is combined with gluconic acid, a natural organic acid found in various fruits and honey. This compound has a high concentration of calcium, making it an effective supplement for increasing calcium levels in the body.

In medical settings, calcium gluconate can be administered orally as a tablet or liquid solution, or it can be given intravenously (directly into a vein) by a healthcare professional. The intravenous route is typically used in emergency situations to quickly raise calcium levels and treat symptoms of hypocalcemia, such as muscle cramps, spasms, or seizures.

It's important to note that while calcium gluconate can be beneficial for treating low calcium levels, it should only be used under the guidance of a healthcare provider, as improper use or overdose can lead to serious side effects, including kidney damage and heart problems.

Calcium carbonate is a chemical compound with the formula CaCO3. It is a common substance found in rocks and in the shells of many marine animals. As a mineral, it is known as calcite or aragonite.

In the medical field, calcium carbonate is often used as a dietary supplement to prevent or treat calcium deficiency. It is also commonly used as an antacid to neutralize stomach acid and relieve symptoms of heartburn, acid reflux, and indigestion.

Calcium carbonate works by reacting with hydrochloric acid in the stomach to form water, carbon dioxide, and calcium chloride. This reaction helps to raise the pH level in the stomach and neutralize excess acid.

It is important to note that excessive use of calcium carbonate can lead to hypercalcemia, a condition characterized by high levels of calcium in the blood, which can cause symptoms such as nausea, vomiting, constipation, confusion, and muscle weakness. Therefore, it is recommended to consult with a healthcare provider before starting any new supplement regimen.

Metabolic bone diseases are a group of conditions that affect the bones and are caused by disorders in the body's metabolism. These disorders can result in changes to the bone structure, density, and strength, leading to an increased risk of fractures and other complications. Some common examples of metabolic bone diseases include:

1. Osteoporosis: a condition characterized by weak and brittle bones that are more likely to break, often as a result of age-related bone loss or hormonal changes.
2. Paget's disease of bone: a chronic disorder that causes abnormal bone growth and deformities, leading to fragile and enlarged bones.
3. Osteomalacia: a condition caused by a lack of vitamin D or problems with the body's ability to absorb it, resulting in weak and soft bones.
4. Hyperparathyroidism: a hormonal disorder that causes too much parathyroid hormone to be produced, leading to bone loss and other complications.
5. Hypoparathyroidism: a hormonal disorder that results in low levels of parathyroid hormone, causing weak and brittle bones.
6. Renal osteodystrophy: a group of bone disorders that occur as a result of chronic kidney disease, including osteomalacia, osteoporosis, and high turnover bone disease.

Treatment for metabolic bone diseases may include medications to improve bone density and strength, dietary changes, exercise, and lifestyle modifications. In some cases, surgery may be necessary to correct bone deformities or fractures.

Calciphylaxis is a rare but serious medical condition characterized by the formation of calcium deposits in small blood vessels and surrounding tissues, particularly in the skin and fatty tissue beneath the skin. This can lead to tissue death (necrosis) and ulceration, often resulting in severe pain, infection, and other complications.

Calciphylaxis is most commonly seen in patients with chronic kidney disease or end-stage renal failure, although it has also been reported in patients with normal kidney function. Other risk factors include obesity, female gender, diabetes, and use of warfarin or corticosteroids.

The exact cause of calciphylaxis is not fully understood, but it is believed to involve a combination of factors such as abnormal mineral metabolism, inflammation, and vascular injury. Treatment typically involves addressing any underlying medical conditions, wound care, and sometimes surgical debridement or skin grafting. In some cases, medications such as sodium thiosulfate or bisphosphonates may be used to help dissolve the calcium deposits and improve symptoms.

Vitamin D deficiency is a condition characterized by insufficient levels of vitamin D in the body, typically defined as a serum 25-hydroxyvitamin D level below 20 nanograms per milliliter (ng/mL) or 50 nanomoles per liter (nmol/L). Vitamin D is an essential fat-soluble vitamin that plays a crucial role in maintaining healthy bones and teeth by regulating the absorption of calcium and phosphorus. It also has various other functions in the body, including modulation of cell growth, immune function, and neuromuscular activity.

Vitamin D can be obtained through dietary sources such as fatty fish, fortified dairy products, and supplements, but the majority of vitamin D is produced in the skin upon exposure to sunlight. Deficiency can occur due to inadequate dietary intake, insufficient sun exposure, or impaired absorption or metabolism of vitamin D.

Risk factors for vitamin D deficiency include older age, darker skin tone, obesity, malabsorption syndromes, liver or kidney disease, and certain medications. Symptoms of vitamin D deficiency can be subtle and nonspecific, such as fatigue, bone pain, muscle weakness, and mood changes. However, prolonged deficiency can lead to more severe health consequences, including osteoporosis, osteomalacia, and increased risk of fractures.

Hydroxycholecalciferols are metabolites of vitamin D that are formed in the liver and kidneys. They are important for maintaining calcium homeostasis in the body by promoting the absorption of calcium from the gut and reabsorption of calcium from the kidneys.

The two main forms of hydroxycholecalciferols are 25-hydroxyvitamin D (25(OH)D) and 1,25-dihydroxyvitamin D (1,25(OH)2D). 25-hydroxyvitamin D is the major circulating form of vitamin D in the body and is used as a clinical measure of vitamin D status. It is converted to 1,25-dihydroxyvitamin D in the kidneys by the enzyme 1α-hydroxylase, which is activated in response to low serum calcium or high phosphate levels.

1,25-dihydroxyvitamin D is the biologically active form of vitamin D and plays a critical role in regulating calcium homeostasis by increasing intestinal calcium absorption and promoting bone health. Deficiency in hydroxycholecalciferols can lead to rickets in children and osteomalacia or osteoporosis in adults, characterized by weakened bones and increased risk of fractures.

Calcium metabolism disorders refer to a group of medical conditions that affect the body's ability to properly regulate the levels of calcium in the blood and tissues. Calcium is an essential mineral that plays a critical role in many bodily functions, including bone health, muscle contraction, nerve function, and blood clotting.

There are several types of calcium metabolism disorders, including:

1. Hypocalcemia: This is a condition characterized by low levels of calcium in the blood. It can be caused by various factors such as vitamin D deficiency, hypoparathyroidism, and certain medications. Symptoms may include muscle cramps, spasms, and tingling sensations in the fingers and toes.
2. Hypercalcemia: This is a condition characterized by high levels of calcium in the blood. It can be caused by various factors such as hyperparathyroidism, cancer, and certain medications. Symptoms may include fatigue, weakness, confusion, and kidney stones.
3. Osteoporosis: This is a condition characterized by weak and brittle bones due to low calcium levels in the bones. It can be caused by various factors such as aging, menopause, vitamin D deficiency, and certain medications. Symptoms may include bone fractures and loss of height.
4. Paget's disease: This is a condition characterized by abnormal bone growth and deformities due to disordered calcium metabolism. It can be caused by various factors such as genetics, age, and certain medications. Symptoms may include bone pain, fractures, and deformities.

Treatment for calcium metabolism disorders depends on the underlying cause of the condition. It may involve supplements, medication, dietary changes, or surgery. Proper diagnosis and management are essential to prevent complications such as kidney stones, bone fractures, and neurological damage.

Minimally invasive surgical procedures are a type of surgery that is performed with the assistance of specialized equipment and techniques to minimize trauma to the patient's body. This approach aims to reduce blood loss, pain, and recovery time as compared to traditional open surgeries. The most common minimally invasive surgical procedure is laparoscopy, which involves making small incisions (usually 0.5-1 cm) in the abdomen or chest and inserting a thin tube with a camera (laparoscope) to visualize the internal organs.

The surgeon then uses long, slender instruments inserted through separate incisions to perform the necessary surgical procedures, such as cutting, coagulation, or suturing. Other types of minimally invasive surgical procedures include arthroscopy (for joint surgery), thoracoscopy (for chest surgery), and hysteroscopy (for uterine surgery). The benefits of minimally invasive surgical procedures include reduced postoperative pain, shorter hospital stays, quicker return to normal activities, and improved cosmetic results. However, not all surgeries can be performed using minimally invasive techniques, and the suitability of a particular procedure depends on various factors, including the patient's overall health, the nature and extent of the surgical problem, and the surgeon's expertise.

Kidney calculi, also known as kidney stones, are hard deposits made of minerals and salts that form inside your kidneys. They can range in size from a grain of sand to a golf ball. When they're small enough, they can be passed through your urine without causing too much discomfort. However, larger stones may block the flow of urine, causing severe pain and potentially leading to serious complications such as urinary tract infections or kidney damage if left untreated.

The formation of kidney calculi is often associated with factors like dehydration, high levels of certain minerals in your urine, family history, obesity, and certain medical conditions such as gout or inflammatory bowel disease. Symptoms of kidney stones typically include severe pain in the back, side, lower abdomen, or groin; nausea and vomiting; fever and chills if an infection is present; and blood in the urine. Treatment options depend on the size and location of the stone but may include medications to help pass the stone, shock wave lithotripsy to break up the stone, or surgical removal of the stone in severe cases.

Calcinosis is a medical condition characterized by the abnormal deposit of calcium salts in various tissues of the body, commonly under the skin or in the muscles and tendons. These calcium deposits can form hard lumps or nodules that can cause pain, inflammation, and restricted mobility. Calcinosis can occur as a complication of other medical conditions, such as autoimmune disorders, kidney disease, and hypercalcemia (high levels of calcium in the blood). In some cases, the cause of calcinosis may be unknown. Treatment for calcinosis depends on the underlying cause and may include medications to manage calcium levels, physical therapy, and surgical removal of large deposits.

Oxyphil cells, also known as oncocytes, are large granular cells with abundant mitochondria. They can be found in various organs, including the thyroid gland, parathyroid gland, salivary glands, and skin. In the thyroid gland, oxyphil cells are often observed in the context of follicular adenomas or follicular carcinomas, where they can make up a significant portion of the tumor. The exact function of oxyphil cells is not well understood, but it is thought that they may play a role in the production and metabolism of hormones or other substances. In general, the presence of oxyphil cells in a tumor is not considered to be indicative of a specific type or behavior of the tumor, but rather a histological feature that can be observed in a variety of contexts.

Hypophosphatemia is a medical condition characterized by abnormally low levels of phosphate (phosphorus) in the blood, specifically below 2.5 mg/dL. Phosphate is an essential electrolyte that plays a crucial role in various bodily functions such as energy production, bone formation, and maintaining acid-base balance.

Hypophosphatemia can result from several factors, including malnutrition, vitamin D deficiency, alcoholism, hormonal imbalances, and certain medications. Symptoms of hypophosphatemia may include muscle weakness, fatigue, bone pain, confusion, and respiratory failure in severe cases. Treatment typically involves correcting the underlying cause and administering phosphate supplements to restore normal levels.

Bone density refers to the amount of bone mineral content (usually measured in grams) in a given volume of bone (usually measured in cubic centimeters). It is often used as an indicator of bone strength and fracture risk. Bone density is typically measured using dual-energy X-ray absorptiometry (DXA) scans, which provide a T-score that compares the patient's bone density to that of a young adult reference population. A T-score of -1 or above is considered normal, while a T-score between -1 and -2.5 indicates osteopenia (low bone mass), and a T-score below -2.5 indicates osteoporosis (porous bones). Regular exercise, adequate calcium and vitamin D intake, and medication (if necessary) can help maintain or improve bone density and prevent fractures.

Phosphorus metabolism disorders refer to a group of conditions that affect the body's ability to properly regulate the levels and utilization of phosphorus. Phosphorus is an essential mineral that plays a critical role in many biological processes, including energy production, bone formation, and nerve function.

Disorders of phosphorus metabolism can result from genetic defects, kidney dysfunction, vitamin D deficiency, or other medical conditions. These disorders can lead to abnormal levels of phosphorus in the blood, which can cause a range of symptoms, including muscle weakness, bone pain, seizures, and respiratory failure.

Examples of phosphorus metabolism disorders include:

1. Hypophosphatemia: This is a condition characterized by low levels of phosphorus in the blood. It can be caused by various factors, such as malnutrition, vitamin D deficiency, and kidney dysfunction.
2. Hyperphosphatemia: This is a condition characterized by high levels of phosphorus in the blood. It can be caused by kidney failure, tumor lysis syndrome, and certain medications.
3. Hereditary hypophosphatemic rickets: This is a genetic disorder that affects the body's ability to regulate vitamin D and phosphorus metabolism. It can lead to weakened bones and skeletal deformities.
4. Oncogenic osteomalacia: This is a rare condition that occurs when tumors produce substances that interfere with phosphorus metabolism, leading to bone pain and weakness.

Treatment for phosphorus metabolism disorders depends on the underlying cause of the disorder and may include dietary changes, supplements, medications, or surgery.

Jaw neoplasms refer to abnormal growths or tumors in the jawbone (mandible) or maxilla (upper jaw). These growths can be benign (non-cancerous) or malignant (cancerous). Benign neoplasms are not considered life-threatening, but they can still cause problems by invading nearby tissues and causing damage. Malignant neoplasms, on the other hand, can spread to other parts of the body and can be life-threatening if not treated promptly and effectively.

Jaw neoplasms can present with various symptoms such as swelling, pain, loose teeth, numbness or tingling in the lips or tongue, difficulty chewing or swallowing, and jaw stiffness or limited movement. The diagnosis of jaw neoplasms typically involves a thorough clinical examination, imaging studies such as X-rays, CT scans, or MRI, and sometimes a biopsy to determine the type and extent of the tumor.

Treatment options for jaw neoplasms depend on several factors, including the type, size, location, and stage of the tumor, as well as the patient's overall health and medical history. Treatment may involve surgery, radiation therapy, chemotherapy, or a combination of these modalities. Regular follow-up care is essential to monitor for recurrence or metastasis (spread) of the neoplasm.

Sodium Pertechnetate Tc 99m is a radioactive pharmaceutical preparation used in medical diagnostic imaging. It is a technetium-99m radiopharmaceutical, where technetium-99m is a metastable nuclear isomer of technetium-99, which emits gamma rays and has a half-life of 6 hours. Sodium Pertechnetate Tc 99m is used as a contrast agent in various diagnostic procedures, such as imaging of the thyroid, salivary glands, or the brain, to evaluate conditions like inflammation, tumors, or abnormalities in blood flow. It is typically administered intravenously, and its short half-life ensures that the radiation exposure is limited.

Multiple Endocrine Neoplasia (MEN) is a group of inherited disorders characterized by the development of tumors in various endocrine glands, which can lead to overproduction of hormones. There are two main types: MEN type 1 and MEN type 2.

MEN type 1, also known as Wermer's syndrome, is caused by mutations in the MEN1 gene. It typically involves tumors in the parathyroid glands (leading to hyperparathyroidism), pancreas (often gastrinomas or insulinomas), and pituitary gland. Some individuals may also develop tumors in other organs, such as the adrenal glands, lungs, or thyroid gland.

MEN type 2, which includes MEN type 2A and MEN type 2B, is caused by mutations in the RET gene. MEN type 2A involves medullary thyroid carcinoma (MTC), pheochromocytomas (tumors of the adrenal glands), and parathyroid tumors. MEN type 2B includes MTC, pheochromocytomas, neuromas (nerve tissue tumors), and distinctive physical features such as a marfanoid habitus and mucosal neuromas.

Early detection and management of these tumors are crucial to prevent complications from hormone excess or tumor invasion. Regular screening and monitoring are recommended for individuals with MEN, even if they do not have symptoms. Treatment typically involves surgical removal of the affected glands or tumors, along with medications to manage hormonal imbalances.

Thyroidectomy is a surgical procedure where all or part of the thyroid gland is removed. The thyroid gland is a butterfly-shaped endocrine gland located in the neck, responsible for producing hormones that regulate metabolism, growth, and development.

There are different types of thyroidectomy procedures, including:

1. Total thyroidectomy: Removal of the entire thyroid gland.
2. Partial (or subtotal) thyroidectomy: Removal of a portion of the thyroid gland.
3. Hemithyroidectomy: Removal of one lobe of the thyroid gland, often performed to treat benign solitary nodules or differentiated thyroid cancer.

Thyroidectomy may be recommended for various reasons, such as treating thyroid nodules, goiter, hyperthyroidism (overactive thyroid), or thyroid cancer. Potential risks and complications of the procedure include bleeding, infection, damage to nearby structures like the parathyroid glands and recurrent laryngeal nerve, and hypoparathyroidism or hypothyroidism due to removal of or damage to the parathyroid glands or thyroid gland, respectively. Close postoperative monitoring and management are essential to minimize these risks and ensure optimal patient outcomes.

Calcitriol receptors, also known as Vitamin D receptors (VDR), are nuclear receptor proteins that bind to calcitriol (1,25-dihydroxyvitamin D3), the active form of vitamin D. These receptors are found in various tissues and cells throughout the body, including the small intestine, bone, kidney, and parathyroid gland.

When calcitriol binds to its receptor, it forms a complex that regulates the expression of genes involved in calcium and phosphate homeostasis, cell growth, differentiation, and immune function. Calcitriol receptors play a critical role in maintaining normal levels of calcium and phosphate in the blood by increasing the absorption of these minerals from the gut, promoting bone mineralization, and regulating the production of parathyroid hormone (PTH).

Calcitriol receptors have also been implicated in various disease processes, including cancer, autoimmune disorders, and infectious diseases. Modulation of calcitriol receptor activity has emerged as a potential therapeutic strategy for the treatment of these conditions.

Kidney disease, also known as nephropathy or renal disease, refers to any functional or structural damage to the kidneys that impairs their ability to filter blood, regulate electrolytes, produce hormones, and maintain fluid balance. This damage can result from a wide range of causes, including diabetes, hypertension, glomerulonephritis, polycystic kidney disease, lupus, infections, drugs, toxins, and congenital or inherited disorders.

Depending on the severity and progression of the kidney damage, kidney diseases can be classified into two main categories: acute kidney injury (AKI) and chronic kidney disease (CKD). AKI is a sudden and often reversible loss of kidney function that occurs over hours to days, while CKD is a progressive and irreversible decline in kidney function that develops over months or years.

Symptoms of kidney diseases may include edema, proteinuria, hematuria, hypertension, electrolyte imbalances, metabolic acidosis, anemia, and decreased urine output. Treatment options depend on the underlying cause and severity of the disease and may include medications, dietary modifications, dialysis, or kidney transplantation.

Nephrocalcinosis is a medical condition characterized by the deposition of calcium salts in the renal parenchyma, specifically within the tubular epithelial cells and interstitium of the kidneys. This process can lead to chronic inflammation, tissue damage, and ultimately impaired renal function if left untreated.

The condition is often associated with metabolic disorders such as hyperparathyroidism, distal renal tubular acidosis, or hyperoxaluria; medications like loop diuretics, corticosteroids, or calcineurin inhibitors; and chronic kidney diseases. The diagnosis of nephrocalcinosis is typically made through imaging studies such as ultrasound, CT scan, or X-ray. Treatment usually involves addressing the underlying cause, modifying dietary habits, and administering medications to control calcium levels in the body.

Calcium channel agonists are substances that increase the activity or function of calcium channels. Calcium channels are specialized proteins in cell membranes that regulate the flow of calcium ions into and out of cells. They play a crucial role in various physiological processes, including muscle contraction, hormone secretion, and nerve impulse transmission.

Calcium channel agonists can enhance the opening of these channels, leading to an increased influx of calcium ions into the cells. This can result in various pharmacological effects, depending on the type of cell and tissue involved. For example, calcium channel agonists may be used to treat conditions such as hypotension (low blood pressure) or heart block by increasing cardiac contractility and heart rate. However, these agents should be used with caution due to their potential to cause adverse effects, including increased heart rate, hypertension, and arrhythmias.

Examples of calcium channel agonists include drugs such as Bay K 8644, FPL 64176, and A23187. It's important to note that some substances can act as both calcium channel agonists and antagonists, depending on the dose, concentration, or duration of exposure.

Multiple Endocrine Neoplasia Type 2a (MEN 2A) is a rare genetic disorder characterized by the development of tumors in various endocrine glands. It is caused by a mutation in the RET gene. The condition typically involves the following three endocrine glands:

1. Medullary Thyroid Carcinoma (MTC): Almost all patients with MEN 2A develop this type of thyroid cancer, which arises from the parafollicular cells (also known as C cells) of the thyroid gland.

2. Pheochromocytomas: These are tumors that develop in the adrenal glands, usually in the chromaffin cells. They can cause the release of excessive amounts of catecholamines, leading to hypertension and other symptoms. Approximately 50% of MEN 2A patients will develop pheochromocytomas.

3. Primary Parathyroid Hyperplasia or Adenomas: Overactivity of the parathyroid glands can lead to hyperparathyroidism, which results in increased calcium levels in the blood (hypercalcemia). This occurs in about 20% of MEN 2A patients.

MEN 2A is an autosomal dominant disorder, meaning that if one parent has the condition, there is a 50% chance their offspring will inherit the mutated gene and develop the disease. Early detection and treatment of the associated tumors can significantly improve patient outcomes.

Radiopharmaceuticals are defined as pharmaceutical preparations that contain radioactive isotopes and are used for diagnosis or therapy in nuclear medicine. These compounds are designed to interact specifically with certain biological targets, such as cells, tissues, or organs, and emit radiation that can be detected and measured to provide diagnostic information or used to destroy abnormal cells or tissue in therapeutic applications.

The radioactive isotopes used in radiopharmaceuticals have carefully controlled half-lives, which determine how long they remain radioactive and how long the pharmaceutical preparation remains effective. The choice of radioisotope depends on the intended use of the radiopharmaceutical, as well as factors such as its energy, range of emission, and chemical properties.

Radiopharmaceuticals are used in a wide range of medical applications, including imaging, cancer therapy, and treatment of other diseases and conditions. Examples of radiopharmaceuticals include technetium-99m for imaging the heart, lungs, and bones; iodine-131 for treating thyroid cancer; and samarium-153 for palliative treatment of bone metastases.

The use of radiopharmaceuticals requires specialized training and expertise in nuclear medicine, as well as strict adherence to safety protocols to minimize radiation exposure to patients and healthcare workers.

Bone resorption is the process by which bone tissue is broken down and absorbed into the body. It is a normal part of bone remodeling, in which old or damaged bone tissue is removed and new tissue is formed. However, excessive bone resorption can lead to conditions such as osteoporosis, in which bones become weak and fragile due to a loss of density. This process is carried out by cells called osteoclasts, which break down the bone tissue and release minerals such as calcium into the bloodstream.

Bone remodeling is the normal and continuous process by which bone tissue is removed from the skeleton (a process called resorption) and new bone tissue is formed (a process called formation). This ongoing cycle allows bones to repair microdamage, adjust their size and shape in response to mechanical stress, and maintain mineral homeostasis. The cells responsible for bone resorption are osteoclasts, while the cells responsible for bone formation are osteoblasts. These two cell types work together to maintain the structural integrity and health of bones throughout an individual's life.

During bone remodeling, the process can be divided into several stages:

1. Activation: The initiation of bone remodeling is triggered by various factors such as microdamage, hormonal changes, or mechanical stress. This leads to the recruitment and activation of osteoclast precursor cells.
2. Resorption: Osteoclasts attach to the bone surface and create a sealed compartment called a resorption lacuna. They then secrete acid and enzymes that dissolve and digest the mineralized matrix, creating pits or cavities on the bone surface. This process helps remove old or damaged bone tissue and releases calcium and phosphate ions into the bloodstream.
3. Reversal: After resorption is complete, the osteoclasts undergo apoptosis (programmed cell death), and mononuclear cells called reversal cells appear on the resorbed surface. These cells prepare the bone surface for the next stage by cleaning up debris and releasing signals that attract osteoblast precursors.
4. Formation: Osteoblasts, derived from mesenchymal stem cells, migrate to the resorbed surface and begin producing a new organic matrix called osteoid. As the osteoid mineralizes, it forms a hard, calcified structure that gradually replaces the resorbed bone tissue. The osteoblasts may become embedded within this newly formed bone as they differentiate into osteocytes, which are mature bone cells responsible for maintaining bone homeostasis and responding to mechanical stress.
5. Mineralization: Over time, the newly formed bone continues to mineralize, becoming stronger and more dense. This process helps maintain the structural integrity of the skeleton and ensures adequate calcium storage.

Throughout this continuous cycle of bone remodeling, hormones, growth factors, and mechanical stress play crucial roles in regulating the balance between resorption and formation. Disruptions to this delicate equilibrium can lead to various bone diseases, such as osteoporosis, where excessive resorption results in weakened bones and increased fracture risk.

Preoperative care refers to the series of procedures, interventions, and preparations that are conducted before a surgical operation. The primary goal of preoperative care is to ensure the patient's well-being, optimize their physical condition, reduce potential risks, and prepare them mentally and emotionally for the upcoming surgery.

Preoperative care typically includes:

1. Preoperative assessment: A thorough evaluation of the patient's overall health status, including medical history, physical examination, laboratory tests, and diagnostic imaging, to identify any potential risk factors or comorbidities that may impact the surgical procedure and postoperative recovery.
2. Informed consent: The process of ensuring the patient understands the nature of the surgery, its purpose, associated risks, benefits, and alternative treatment options. The patient signs a consent form indicating they have been informed and voluntarily agree to undergo the surgery.
3. Preoperative instructions: Guidelines provided to the patient regarding their diet, medication use, and other activities in the days leading up to the surgery. These instructions may include fasting guidelines, discontinuing certain medications, or arranging for transportation after the procedure.
4. Anesthesia consultation: A meeting with the anesthesiologist to discuss the type of anesthesia that will be used during the surgery and address any concerns related to anesthesia risks, side effects, or postoperative pain management.
5. Preparation of the surgical site: Cleaning and shaving the area where the incision will be made, as well as administering appropriate antimicrobial agents to minimize the risk of infection.
6. Medical optimization: Addressing any underlying medical conditions or correcting abnormalities that may negatively impact the surgical outcome. This may involve adjusting medications, treating infections, or managing chronic diseases such as diabetes.
7. Emotional and psychological support: Providing counseling, reassurance, and education to help alleviate anxiety, fear, or emotional distress related to the surgery.
8. Preoperative holding area: The patient is transferred to a designated area near the operating room where they are prepared for surgery by changing into a gown, having intravenous (IV) lines inserted, and receiving monitoring equipment.

By following these preoperative care guidelines, healthcare professionals aim to ensure that patients undergo safe and successful surgical procedures with optimal outcomes.

An Immunoradiometric Assay (IRMA) is a type of radioimmunoassay (RIA), which is a technique used in clinical laboratories to measure the concentration of specific analytes, such as hormones, drugs, or vitamins, in biological samples. In an IRMA, the sample containing the unknown amount of the analyte is incubated with a known quantity of a labeled antibody that specifically binds to the analyte.

The labeled antibody is usually radiolabeled with a radioisotope such as iodine-125 (^125^I) or tritium (^3^H). During the incubation, the labeled antibody binds to the analyte in the sample, forming an immune complex. The unbound labeled antibody is then separated from the immune complex by a variety of methods such as precipitation, centrifugation, or chromatography.

The amount of radioactivity in the pellet (immune complex) is measured using a gamma counter (for ^125^I) or liquid scintillation counter (for ^3^H). The amount of radioactivity is directly proportional to the amount of analyte present in the sample. By comparing the radioactivity in the sample to a standard curve prepared with known concentrations of the analyte, the concentration of the analyte in the sample can be determined.

IRMAs are highly sensitive and specific assays that can detect very low levels of analytes in biological samples. However, they require specialized equipment and handling procedures due to the use of radioisotopes.

Dietary Phosphorus is a mineral that is an essential nutrient for human health. It is required for the growth, maintenance, and repair of body tissues, including bones and teeth. Phosphorus is also necessary for the production of energy, the formation of DNA and RNA, and the regulation of various physiological processes.

In the diet, phosphorus is primarily found in protein-containing foods such as meat, poultry, fish, dairy products, legumes, and nuts. It can also be found in processed foods that contain additives such as phosphoric acid, which is used to enhance flavor or as a preservative.

The recommended daily intake of phosphorus for adults is 700 milligrams (mg) per day. However, it's important to note that excessive intake of phosphorus, particularly from supplements and fortified foods, can lead to health problems such as kidney damage and calcification of soft tissues. Therefore, it's recommended to obtain phosphorus primarily from whole foods rather than supplements.

A giant cell granuloma is a type of non-cancerous (benign) lesion characterized by the presence of large collections of immune cells called macrophages, which have fused together to form multinucleated giant cells. These lesions can occur in various tissues throughout the body but are most commonly found in the oral cavity and jawbone.

Giant cell granulomas can be further classified into two types: central (or bone) giant cell granuloma and peripheral giant cell granuloma. Central giant cell granulomas arise from the bone, while peripheral giant cell granulomas occur in the soft tissues of the gingiva or mouth lining.

Central giant cell granulomas are more aggressive than peripheral ones and can cause significant bone destruction if left untreated. They typically affect younger individuals, with a higher prevalence in females than males. The exact cause of central giant cell granulomas is not well understood but may be associated with local trauma, hormonal imbalances, or genetic factors.

Peripheral giant cell granulomas are less aggressive and usually present as painless, slow-growing nodules on the gums. They typically affect adults, with a higher prevalence in females than males. Peripheral giant cell granulomas may be associated with local irritants such as plaque, calculus, or dental restorations.

Treatment for giant cell granulomas depends on their size, location, and aggressiveness. Surgical excision is the most common treatment approach, but other options such as curettage, corticosteroid injections, or medication therapy may also be considered. Regular follow-up appointments with a healthcare provider are essential to monitor for recurrence.

Ectopic hormone production refers to the situation when a hormone is produced in an unusual location or by a type of cell that does not typically produce it. This can occur due to various reasons such as genetic mutations, cancer, or other medical conditions. The ectopic hormone production can lead to hormonal imbalances and related symptoms, as the regulation of hormones in the body becomes disrupted.

For example, in some cases of lung cancer, the tumor cells may produce adrenocorticotropic hormone (ACTH), which is typically produced by the pituitary gland. This ectopic ACTH production can result in Cushing's syndrome, a condition characterized by symptoms such as weight gain, muscle weakness, and high blood pressure.

It's important to note that ectopic hormone production is relatively rare and usually occurs in the context of specific medical conditions. If you suspect that you or someone else may have ectopic hormone production, it's important to seek medical attention from a healthcare professional who can provide appropriate evaluation and treatment.

Pseudohypoparathyroidism (PHP) is a rare genetic disorder characterized by the body's resistance to the action of parathyroid hormone (PTH), leading to hypocalcemia (low serum calcium levels) and hyperphosphatemia (high serum phosphate levels). Despite normal or elevated PTH levels, target organs such as the kidneys and bones do not respond appropriately to its actions.

There are several types of PHP, with the most common being type Ia, which is caused by mutations in the GNAS gene. This gene provides instructions for making a protein called the alpha-subunit of the stimulatory G protein (Gs-alpha), which plays a crucial role in transmitting signals within cells. In PHP type Ia, there is a reduced amount or functionally impaired Gs-alpha protein, leading to resistance to PTH and other hormones that use this signaling pathway, such as thyroid-stimulating hormone (TSH) and gonadotropins.

PHP type Ia patients often exhibit physical features known as Albright's hereditary osteodystrophy (AHO), including short stature, round face, obesity, brachydactyly (shortened fingers and toes), and ectopic ossifications (formation of bone in abnormal places). However, it is important to note that not all individuals with AHO have PHP, and not all PHP patients display AHO features.

PHP type Ib is another common form of the disorder, characterized by PTH resistance without the physical manifestations of AHO. This type is caused by mutations in the STX16 gene or other genes involved in the intracellular trafficking of Gs-alpha protein.

Pseudohypoparathyroidism should be differentiated from hypoparathyroidism, a condition where there is an insufficient production or secretion of PTH by the parathyroid glands, leading to similar biochemical abnormalities but without resistance to PTH action.

Aniline compounds, also known as aromatic amines, are organic compounds that contain a benzene ring substituted with an amino group (-NH2). Aniline itself is the simplest and most common aniline compound, with the formula C6H5NH2.

Aniline compounds are important in the chemical industry and are used in the synthesis of a wide range of products, including dyes, pharmaceuticals, and rubber chemicals. They can be produced by reducing nitrobenzene or by directly substituting ammonia onto benzene in a process called amination.

It is important to note that aniline compounds are toxic and can cause serious health effects, including damage to the liver, kidneys, and central nervous system. They can also be absorbed through the skin and are known to have carcinogenic properties. Therefore, appropriate safety measures must be taken when handling aniline compounds.

Osteitis deformans, also known as Paget's disease of bone, is a chronic disorder of the bone characterized by abnormal turnover and remodeling of the bone. In this condition, the bone becomes enlarged, thickened, and deformed due to excessive and disorganized bone formation and resorption.

The process begins when the bone-remodeling cycle is disrupted, leading to an imbalance between the activity of osteoclasts (cells that break down bone) and osteoblasts (cells that form new bone). In Paget's disease, osteoclasts become overactive and increase bone resorption, followed by an overzealous response from osteoblasts, which attempt to repair the damage but do so in a disorganized manner.

The affected bones can become weakened, prone to fractures, and may cause pain, deformities, or other complications such as arthritis, hearing loss, or neurological symptoms if the skull or spine is involved. The exact cause of Paget's disease remains unknown, but it is believed that genetic and environmental factors play a role in its development.

Early diagnosis and treatment can help manage the symptoms and prevent complications associated with osteitis deformans. Treatment options include medications to slow down bone turnover, pain management, and orthopedic interventions when necessary.

Tetany is a medical condition characterized by involuntary muscle spasms and cramps, often starting in the hands and feet and can spread to other parts of the body. It is typically caused by an imbalance of minerals such as calcium and magnesium in the blood, which can be due to various underlying medical conditions such as hypoparathyroidism, hypocalcemia, or alkalosis. Tetany can also occur after surgical removal of the parathyroid glands (a procedure called parathyroidectomy). In some cases, tetany can be a symptom of other neuromuscular disorders.

The muscle spasms associated with tetany can be painful and can interfere with normal functioning. They are often triggered by sensory stimuli such as touch, sound, or temperature changes. Tetany can also cause numbness, tingling, or a crawling sensation in the skin (paresthesia). In severe cases, it can lead to seizures, difficulty breathing, and cardiac arrhythmias.

Treatment of tetany typically involves addressing the underlying medical condition causing the imbalance of minerals in the blood. This may involve supplementation with calcium or magnesium, medication to regulate parathyroid hormone levels, or other treatments depending on the specific cause.

Treatment outcome is a term used to describe the result or effect of medical treatment on a patient's health status. It can be measured in various ways, such as through symptoms improvement, disease remission, reduced disability, improved quality of life, or survival rates. The treatment outcome helps healthcare providers evaluate the effectiveness of a particular treatment plan and make informed decisions about future care. It is also used in clinical research to compare the efficacy of different treatments and improve patient care.

Creatinine is a waste product that's produced by your muscles and removed from your body by your kidneys. Creatinine is a breakdown product of creatine, a compound found in meat and fish, as well as in the muscles of vertebrates, including humans.

In healthy individuals, the kidneys filter out most of the creatinine and eliminate it through urine. However, when the kidneys are not functioning properly, creatinine levels in the blood can rise. Therefore, measuring the amount of creatinine in the blood or urine is a common way to test how well the kidneys are working. High creatinine levels in the blood may indicate kidney damage or kidney disease.

Calcifediol is the medical term for 25-hydroxyvitamin D, which is a form of vitamin D that is produced in the liver when it processes vitamin D from sunlight or from dietary sources. It is an important precursor to the active form of vitamin D, calcitriol, and is often used as a supplement for people who have low levels of vitamin D. Calcifediol is converted to calcitriol in the kidneys, where it plays a role in regulating calcium and phosphate levels in the body, which are important for maintaining healthy bones and teeth.

Kidney transplantation is a surgical procedure where a healthy kidney from a deceased or living donor is implanted into a patient with end-stage renal disease (ESRD) or permanent kidney failure. The new kidney takes over the functions of filtering waste and excess fluids from the blood, producing urine, and maintaining the body's electrolyte balance.

The transplanted kidney is typically placed in the lower abdomen, with its blood vessels connected to the recipient's iliac artery and vein. The ureter of the new kidney is then attached to the recipient's bladder to ensure proper urine flow. Following the surgery, the patient will require lifelong immunosuppressive therapy to prevent rejection of the transplanted organ by their immune system.

Recurrence, in a medical context, refers to the return of symptoms or signs of a disease after a period of improvement or remission. It indicates that the condition has not been fully eradicated and may require further treatment. Recurrence is often used to describe situations where a disease such as cancer comes back after initial treatment, but it can also apply to other medical conditions. The likelihood of recurrence varies depending on the type of disease and individual patient factors.

Endocrine surgical procedures refer to the surgical removal or manipulation of endocrine glands or related structures. Endocrine glands are specialized organs that produce, store, and secrete hormones directly into the bloodstream. These hormones regulate various physiological processes in the body, including metabolism, growth, development, and reproduction.

Some common endocrine surgical procedures include:

1. Thyroidectomy: Surgical removal of all or part of the thyroid gland, which is located in the neck and produces hormones regulating metabolism. Indications for thyroidectomy may include thyroid cancer, benign thyroid nodules, hyperthyroidism, and Graves' disease.
2. Parathyroidectomy: Surgical removal of one or more parathyroid glands, which are located near the thyroid gland and regulate calcium levels in the blood. Indications for parathyroidectomy may include hyperparathyroidism, parathyroid tumors, and kidney stones caused by high calcium levels.
3. Adrenalectomy: Surgical removal of one or both adrenal glands, which are located on top of the kidneys and produce hormones regulating stress response, metabolism, and blood pressure. Indications for adrenalectomy may include adrenal cancer, pheochromocytoma, Cushing's syndrome, and Conn's syndrome.
4. Pancreatectomy: Surgical removal of all or part of the pancreas, which is a gland located behind the stomach and produces hormones regulating blood sugar levels (insulin and glucagon) and enzymes for digestion. Indications for pancreatectomy may include pancreatic cancer, chronic pancreatitis, and insulinoma.
5. Neuroendocrine tumor resection: Surgical removal of neuroendocrine tumors, which are rare tumors that arise from hormone-producing cells in various organs, including the pancreas, lung, and gastrointestinal tract. Indications for neuroendocrine tumor resection may include symptoms caused by hormone excess or risk of metastasis.

These surgical procedures are complex and require specialized training and expertise. Patients should consult with a qualified surgeon to discuss the risks and benefits of each procedure and determine the best course of treatment.

Calcitonin is a hormone that is produced and released by the parafollicular cells (also known as C cells) of the thyroid gland. It plays a crucial role in regulating calcium homeostasis in the body. Specifically, it helps to lower elevated levels of calcium in the blood by inhibiting the activity of osteoclasts, which are bone cells that break down bone tissue and release calcium into the bloodstream. Calcitonin also promotes the uptake of calcium in the bones and increases the excretion of calcium in the urine.

Calcitonin is typically released in response to high levels of calcium in the blood, and its effects help to bring calcium levels back into balance. In addition to its role in calcium regulation, calcitonin may also have other functions in the body, such as modulating immune function and reducing inflammation.

Clinically, synthetic forms of calcitonin are sometimes used as a medication to treat conditions related to abnormal calcium levels, such as hypercalcemia (high blood calcium) or osteoporosis. Calcitonin can be administered as an injection, nasal spray, or oral tablet, depending on the specific formulation and intended use.

Renal insufficiency, also known as kidney failure, is a medical condition in which the kidneys are unable to properly filter waste products and excess fluids from the blood. This results in a buildup of these substances in the body, which can cause a variety of symptoms such as weakness, shortness of breath, and fluid retention. Renal insufficiency can be acute, meaning it comes on suddenly, or chronic, meaning it develops over time. It is typically diagnosed through blood tests, urine tests, and imaging studies. Treatment may include medications to control symptoms, dietary changes, and in severe cases, dialysis or a kidney transplant.

Fluoride poisoning, also known as fluoride toxicity, is a condition that occurs when someone ingests too much fluoride. This can lead to a variety of symptoms, including nausea, vomiting, diarrhea, abdominal pain, excessive saliva, and weakness. In severe cases, it can cause more serious problems, such as seizures, coma, or even death.

Fluoride is a naturally occurring mineral that is often added to drinking water and toothpaste in order to help prevent tooth decay. However, consuming too much fluoride can be harmful. The amount of fluoride that is considered safe for human consumption depends on a number of factors, including age, weight, and overall health.

Fluoride poisoning is usually caused by accidental ingestion of large amounts of fluoride-containing products, such as toothpaste or mouthwash. It can also occur if someone drinks water that has been contaminated with high levels of fluoride. In some cases, fluoride poisoning may be the result of industrial accidents or intentional poisoning.

If you suspect that you or someone else has ingested too much fluoride, it is important to seek medical attention immediately. Treatment for fluoride poisoning typically involves supportive care, such as administering fluids to help flush the fluoride out of the body. In severe cases, more invasive treatments may be necessary.

Intraoperative care refers to the medical care and interventions provided to a patient during a surgical procedure. This care is typically administered by a team of healthcare professionals, including anesthesiologists, surgeons, nurses, and other specialists as needed. The goal of intraoperative care is to maintain the patient's physiological stability throughout the surgery, minimize complications, and ensure the best possible outcome.

Intraoperative care may include:

1. Anesthesia management: Administering and monitoring anesthetic drugs to keep the patient unconscious and free from pain during the surgery.
2. Monitoring vital signs: Continuously tracking the patient's heart rate, blood pressure, oxygen saturation, body temperature, and other key physiological parameters to ensure they remain within normal ranges.
3. Fluid and blood product administration: Maintaining adequate intravascular volume and oxygen-carrying capacity through the infusion of fluids and blood products as needed.
4. Intraoperative imaging: Utilizing real-time imaging techniques, such as X-ray, ultrasound, or CT scans, to guide the surgical procedure and ensure accurate placement of implants or other devices.
5. Neuromonitoring: Using electrophysiological methods to monitor the functional integrity of nerves and neural structures during surgery, particularly in procedures involving the brain, spine, or peripheral nerves.
6. Intraoperative medication management: Administering various medications as needed for pain control, infection prophylaxis, or the treatment of medical conditions that may arise during the surgery.
7. Temperature management: Regulating the patient's body temperature to prevent hypothermia or hyperthermia, which can have adverse effects on surgical outcomes and overall patient health.
8. Communication and coordination: Ensuring effective communication among the members of the surgical team to optimize patient care and safety.

Chondrocalcinosis is a medical condition characterized by the deposition of calcium pyrophosphate dihydrate crystals in the fibrous cartilage (also known as chondral or articular cartilage) and/or the joint cavity (synovial fluid). This cartilage is present in various parts of the body, including the ears, nose, respiratory tract, and connective tissues such as those found in joints.

Calcium pyrophosphate dihydrate crystals are normally present in small amounts within the body; however, an overabundance of these crystals can lead to chondrocalcinosis. The condition is often associated with osteoarthritis and can affect people of all ages but is more common in older adults.

Chondrocalcinosis may not always cause symptoms, but when it does, they can include joint pain, stiffness, swelling, and warmth. These symptoms are similar to those seen in other forms of arthritis, making chondrocalcinosis difficult to diagnose based on symptoms alone. Diagnosis typically involves imaging techniques such as X-rays or ultrasounds, as well as joint fluid analysis to identify the presence of calcium pyrophosphate dihydrate crystals.

Treatment for chondrocalcinosis is generally focused on managing symptoms and addressing any underlying conditions that may contribute to the development or progression of the disease. This can include medications such as nonsteroidal anti-inflammatory drugs (NSAIDs) to reduce pain and inflammation, joint aspiration to remove excess fluid and crystals from the affected area, and physical therapy to maintain joint mobility and strength. In some cases, surgery may be necessary to repair or replace damaged joints.

The arm bones are referred to as the humerus, radius, and ulna. The humerus is the upper arm bone that connects the shoulder to the elbow. The radius and ulna are the two bones in the forearm that extend from the elbow to the wrist. Together, these bones provide stability, support, and mobility for the arm and upper limb.

Zollinger-Ellison Syndrome (ZES) is a rare digestive disorder that is characterized by the development of one or more gastrin-secreting tumors, also known as gastrinomas. These tumors are usually found in the pancreas and duodenum (the first part of the small intestine). Gastrinomas produce excessive amounts of the hormone gastrin, which leads to the overproduction of stomach acid.

The increased stomach acid can cause severe peptic ulcers, often multiple or refractory to treatment, in the duodenum and jejunum (the second part of the small intestine). ZES may also result in diarrhea due to the excess acid irritating the intestines. In some cases, gastrinomas can be malignant and metastasize to other organs such as the liver and lymph nodes.

The diagnosis of Zollinger-Ellison Syndrome typically involves measuring serum gastrin levels and performing a secretin stimulation test. Imaging tests like CT scans, MRI, or endoscopic ultrasounds may be used to locate the tumors. Treatment usually includes medications to reduce stomach acid production (such as proton pump inhibitors) and surgery to remove the gastrinomas when possible.

The ilium is the largest and broadest of the three parts that make up the hip bone or coxal bone. It is the uppermost portion of the pelvis and forms the side of the waist. The ilium has a curved, fan-like shape and articulates with the sacrum at the back to form the sacroiliac joint. The large, concave surface on the top of the ilium is called the iliac crest, which can be felt as a prominent ridge extending from the front of the hip to the lower back. This region is significant in orthopedics and physical examinations for its use in assessing various medical conditions and performing certain maneuvers during the physical examination.

Chronic Renal Insufficiency (CRI) is a medical condition characterized by a gradual and progressive loss of kidney function over a period of months or years. It is also known as Chronic Kidney Disease (CKD). The main function of the kidneys is to filter waste products and excess fluids from the blood, which are then excreted in the urine. When the kidneys become insufficient, these waste products and fluids accumulate in the body, leading to various complications.

CRI is defined as a glomerular filtration rate (GFR) of less than 60 ml/min/1.73m2 for three months or more, regardless of cause. GFR is a measure of kidney function that estimates how well the kidneys are filtering waste products from the blood. The condition is classified into five stages based on the severity of the disease and the GFR value.

Stage 1: GFR greater than or equal to 90 ml/min/1.73m2
Stage 2: GFR between 60-89 ml/min/1.73m2
Stage 3: GFR between 30-59 ml/min/1.73m2
Stage 4: GFR between 15-29 ml/min/1.73m2
Stage 5: GFR less than 15 ml/min/1.73m2 or dialysis

CRI can be caused by various underlying conditions such as diabetes, hypertension, glomerulonephritis, polycystic kidney disease, and other genetic or acquired disorders. Symptoms of CRI may include fatigue, weakness, loss of appetite, swelling in the legs and ankles, shortness of breath, and changes in urination patterns. Treatment for CRI focuses on slowing down the progression of the disease, managing symptoms, and preventing complications. This may involve lifestyle modifications, medication, dialysis, or kidney transplantation.

Nephrolithiasis is a medical term that refers to the presence of stones or calculi in the kidney. These stones can form anywhere in the urinary tract, including the kidneys, ureters, bladder, and urethra. Nephrolithiasis is also commonly known as kidney stones.

Kidney stones are hard deposits made up of minerals and salts that crystallize in the urine. They can vary in size from tiny sand-like particles to larger pebble or even golf ball-sized masses. Kidney stones can cause pain, bleeding, and infection if they block the flow of urine through the urinary tract.

The formation of kidney stones is often associated with a variety of factors such as dehydration, high levels of calcium, oxalate, or uric acid in the urine, family history, obesity, and certain medical conditions like gout or inflammatory bowel disease. Treatment for nephrolithiasis depends on the size and location of the stone, as well as the severity of symptoms. Small stones may pass spontaneously with increased fluid intake, while larger stones may require medication, shock wave lithotripsy, or surgical removal.

Bone density conservation agents, also known as anti-resorptive agents or bone-sparing drugs, are a class of medications that help to prevent the loss of bone mass and reduce the risk of fractures. They work by inhibiting the activity of osteoclasts, the cells responsible for breaking down and reabsorbing bone tissue during the natural remodeling process.

Examples of bone density conservation agents include:

1. Bisphosphonates (e.g., alendronate, risedronate, ibandronate, zoledronic acid) - These are the most commonly prescribed class of bone density conservation agents. They bind to hydroxyapatite crystals in bone tissue and inhibit osteoclast activity, thereby reducing bone resorption.
2. Denosumab (Prolia) - This is a monoclonal antibody that targets RANKL (Receptor Activator of Nuclear Factor-κB Ligand), a key signaling molecule involved in osteoclast differentiation and activation. By inhibiting RANKL, denosumab reduces osteoclast activity and bone resorption.
3. Selective estrogen receptor modulators (SERMs) (e.g., raloxifene) - These medications act as estrogen agonists or antagonists in different tissues. In bone tissue, SERMs mimic the bone-preserving effects of estrogen by inhibiting osteoclast activity and reducing bone resorption.
4. Hormone replacement therapy (HRT) - Estrogen hormone replacement therapy has been shown to preserve bone density in postmenopausal women; however, its use is limited due to increased risks of breast cancer, cardiovascular disease, and thromboembolic events.
5. Calcitonin - This hormone, secreted by the thyroid gland, inhibits osteoclast activity and reduces bone resorption. However, it has largely been replaced by other more effective bone density conservation agents.

These medications are often prescribed for individuals at high risk of fractures due to conditions such as osteoporosis or metabolic disorders that affect bone health. It is essential to follow the recommended dosage and administration guidelines to maximize their benefits while minimizing potential side effects. Regular monitoring of bone density, blood calcium levels, and other relevant parameters is also necessary during treatment with these medications.

Osteocalcin is a protein that is produced by osteoblasts, which are the cells responsible for bone formation. It is one of the most abundant non-collagenous proteins found in bones and plays a crucial role in the regulation of bone metabolism. Osteocalcin contains a high affinity for calcium ions, making it essential for the mineralization of the bone matrix.

Once synthesized, osteocalcin is secreted into the extracellular matrix, where it binds to hydroxyapatite crystals, helping to regulate their growth and contributing to the overall strength and integrity of the bones. Osteocalcin also has been found to play a role in other physiological processes outside of bone metabolism, such as modulating insulin sensitivity, energy metabolism, and male fertility.

In summary, osteocalcin is a protein produced by osteoblasts that plays a critical role in bone formation, mineralization, and turnover, and has been implicated in various other physiological processes.

Prospective studies, also known as longitudinal studies, are a type of cohort study in which data is collected forward in time, following a group of individuals who share a common characteristic or exposure over a period of time. The researchers clearly define the study population and exposure of interest at the beginning of the study and follow up with the participants to determine the outcomes that develop over time. This type of study design allows for the investigation of causal relationships between exposures and outcomes, as well as the identification of risk factors and the estimation of disease incidence rates. Prospective studies are particularly useful in epidemiology and medical research when studying diseases with long latency periods or rare outcomes.

Osteosclerosis is a medical term that refers to an abnormal thickening and increased density of bone tissue. This condition can occur as a result of various diseases or conditions, such as certain types of bone cancer, Paget's disease of bone, fluoride poisoning, or chronic infection of the bone. Osteosclerosis can also be seen in some benign conditions, such as osteopetrosis, which is a rare genetic disorder characterized by an excessively hard and dense skeleton.

In some cases, osteosclerosis may not cause any symptoms and may only be discovered on X-rays or other imaging studies. However, in other cases, it can lead to complications such as bone pain, fractures, or deformities. Treatment for osteosclerosis depends on the underlying cause of the condition and may include medications, surgery, or other therapies.

Medullary sponge kidney (MSK) is a congenital kidney disorder characterized by abnormal dilations of the collecting ducts within the medulla of one or both kidneys. These dilations give the appearance of a "sponge-like" structure, hence the name of the condition.

In MSK, the affected collecting ducts become filled with small cysts or sacs that can trap calcium and other minerals, leading to the formation of recurring kidney stones and chronic kidney disease in some cases. The disorder can also cause urinary tract infections (UTIs) and hematuria (blood in the urine).

MSK is usually asymptomatic and often discovered incidentally during imaging studies performed for other reasons. However, when symptoms do occur, they may include recurrent kidney stones, flank pain, UTIs, or hematuria. The exact cause of MSK remains unclear, but it appears to have a genetic component, as it can be associated with certain inherited syndromes such as Tuberous Sclerosis Complex and Ehlers-Danlos syndrome.

MSK is typically managed through preventative measures aimed at reducing the risk of kidney stone formation, such as increasing fluid intake, maintaining a healthy diet, and taking medications to lower urinary calcium levels if necessary. In some cases, surgery may be required to remove large or recurrent stones or to treat complications associated with the disorder.

Follow-up studies are a type of longitudinal research that involve repeated observations or measurements of the same variables over a period of time, in order to understand their long-term effects or outcomes. In medical context, follow-up studies are often used to evaluate the safety and efficacy of medical treatments, interventions, or procedures.

In a typical follow-up study, a group of individuals (called a cohort) who have received a particular treatment or intervention are identified and then followed over time through periodic assessments or data collection. The data collected may include information on clinical outcomes, adverse events, changes in symptoms or functional status, and other relevant measures.

The results of follow-up studies can provide important insights into the long-term benefits and risks of medical interventions, as well as help to identify factors that may influence treatment effectiveness or patient outcomes. However, it is important to note that follow-up studies can be subject to various biases and limitations, such as loss to follow-up, recall bias, and changes in clinical practice over time, which must be carefully considered when interpreting the results.

Intraoperative monitoring (IOM) is the practice of using specialized techniques to monitor physiological functions or neural structures in real-time during surgical procedures. The primary goal of IOM is to provide continuous information about the patient's status and the effects of surgery on neurological function, allowing surgeons to make informed decisions and minimize potential risks.

IOM can involve various methods such as:

1. Electrophysiological monitoring: This includes techniques like somatosensory evoked potentials (SSEP), motor evoked potentials (MEP), and electroencephalography (EEG) to assess the integrity of neural pathways and brain function during surgery.
2. Neuromonitoring: Direct electrical stimulation of nerves or spinal cord structures can help identify critical neuroanatomical structures, evaluate their functional status, and guide surgical interventions.
3. Hemodynamic monitoring: Measuring blood pressure, heart rate, cardiac output, and oxygen saturation helps assess the patient's overall physiological status during surgery.
4. Imaging modalities: Intraoperative imaging techniques like ultrasound, computed tomography (CT), or magnetic resonance imaging (MRI) can provide real-time visualization of anatomical structures and surgical progress.

The specific IOM methods employed depend on the type of surgery, patient characteristics, and potential risks involved. Intraoperative monitoring is particularly crucial in procedures where there is a risk of neurological injury, such as spinal cord or brain surgeries, vascular interventions, or tumor resections near critical neural structures.

In medical terms, the "neck" is defined as the portion of the body that extends from the skull/head to the thorax or chest region. It contains 7 cervical vertebrae, muscles, nerves, blood vessels, lymphatic vessels, and glands (such as the thyroid gland). The neck is responsible for supporting the head, allowing its movement in various directions, and housing vital structures that enable functions like respiration and circulation.

Dihydroxycholecalciferols are a form of calcifediol, which is a type of secosteroid hormone that is produced in the body as a result of the exposure to sunlight and the dietary intake of vitamin D. The term "dihydroxycholecalciferols" specifically refers to the compounds 1,25-dihydroxycholecalciferol (calcitriol) and 24,25-dihydroxycholecalciferol. These compounds are produced in the body through a series of chemical reactions involving enzymes that convert vitamin D into its active forms.

Calcitriol is the biologically active form of vitamin D and plays an important role in regulating the levels of calcium and phosphorus in the blood, as well as promoting the absorption of these minerals from the gut. It also has other functions, such as modulating cell growth and immune function.

24,25-dihydroxycholecalciferol is a less active form of vitamin D that is produced in larger quantities than calcitriol. Its exact role in the body is not well understood, but it is thought to have some effects on calcium metabolism and may play a role in regulating the levels of other hormones in the body.

Dihydroxycholecalciferols are typically measured in the blood as part of an evaluation for vitamin D deficiency or to monitor treatment with vitamin D supplements. Low levels of these compounds can indicate a deficiency, while high levels may indicate excessive intake or impaired metabolism.

In the context of nutrition and health, minerals are inorganic elements that are essential for various bodily functions, such as nerve impulse transmission, muscle contraction, maintaining fluid and electrolyte balance, and bone structure. They are required in small amounts compared to macronutrients (carbohydrates, proteins, and fats) and are obtained from food and water.

Some of the major minerals include calcium, phosphorus, magnesium, sodium, potassium, and chloride, while trace minerals or microminerals are required in even smaller amounts and include iron, zinc, copper, manganese, iodine, selenium, and fluoride.

It's worth noting that the term "minerals" can also refer to geological substances found in the earth, but in medical terminology, it specifically refers to the essential inorganic elements required for human health.

Retrospective studies, also known as retrospective research or looking back studies, are a type of observational study that examines data from the past to draw conclusions about possible causal relationships between risk factors and outcomes. In these studies, researchers analyze existing records, medical charts, or previously collected data to test a hypothesis or answer a specific research question.

Retrospective studies can be useful for generating hypotheses and identifying trends, but they have limitations compared to prospective studies, which follow participants forward in time from exposure to outcome. Retrospective studies are subject to biases such as recall bias, selection bias, and information bias, which can affect the validity of the results. Therefore, retrospective studies should be interpreted with caution and used primarily to generate hypotheses for further testing in prospective studies.

Dietary calcium is a type of calcium that is obtained through food sources. Calcium is an essential mineral that is necessary for many bodily functions, including bone formation and maintenance, muscle contraction, nerve impulse transmission, and blood clotting.

The recommended daily intake of dietary calcium varies depending on age, sex, and other factors. For example, the recommended daily intake for adults aged 19-50 is 1000 mg, while women over 50 and men over 70 require 1200 mg per day.

Good dietary sources of calcium include dairy products such as milk, cheese, and yogurt; leafy green vegetables like broccoli and kale; fortified cereals and juices; and certain types of fish, such as salmon and sardines. It is important to note that some foods can inhibit the absorption of calcium, including oxalates found in spinach and rhubarb, and phytates found in whole grains and legumes.

If a person is unable to get enough calcium through their diet, they may need to take calcium supplements. However, it is important to talk to a healthcare provider before starting any new supplement regimen, as excessive intake of calcium can lead to negative health effects.

A reoperation is a surgical procedure that is performed again on a patient who has already undergone a previous operation for the same or related condition. Reoperations may be required due to various reasons, such as inadequate initial treatment, disease recurrence, infection, or complications from the first surgery. The nature and complexity of a reoperation can vary widely depending on the specific circumstances, but it often carries higher risks and potential complications compared to the original operation.

A biological marker, often referred to as a biomarker, is a measurable indicator that reflects the presence or severity of a disease state, or a response to a therapeutic intervention. Biomarkers can be found in various materials such as blood, tissues, or bodily fluids, and they can take many forms, including molecular, histologic, radiographic, or physiological measurements.

In the context of medical research and clinical practice, biomarkers are used for a variety of purposes, such as:

1. Diagnosis: Biomarkers can help diagnose a disease by indicating the presence or absence of a particular condition. For example, prostate-specific antigen (PSA) is a biomarker used to detect prostate cancer.
2. Monitoring: Biomarkers can be used to monitor the progression or regression of a disease over time. For instance, hemoglobin A1c (HbA1c) levels are monitored in diabetes patients to assess long-term blood glucose control.
3. Predicting: Biomarkers can help predict the likelihood of developing a particular disease or the risk of a negative outcome. For example, the presence of certain genetic mutations can indicate an increased risk for breast cancer.
4. Response to treatment: Biomarkers can be used to evaluate the effectiveness of a specific treatment by measuring changes in the biomarker levels before and after the intervention. This is particularly useful in personalized medicine, where treatments are tailored to individual patients based on their unique biomarker profiles.

It's important to note that for a biomarker to be considered clinically valid and useful, it must undergo rigorous validation through well-designed studies, including demonstrating sensitivity, specificity, reproducibility, and clinical relevance.

Neoplastic pregnancy complications refer to the abnormal growth of cells (neoplasia) that can occur during pregnancy. These growths can be benign or malignant and can arise from any type of tissue in the body. However, when they occur in pregnant women, they can pose unique challenges due to the potential effects on the developing fetus and the changes in the mother's body.

Some common neoplastic pregnancy complications include:

1. Gestational trophoblastic disease (GTD): This is a group of rare tumors that occur in the uterus during pregnancy. GTD can range from benign conditions like hydatidiform mole to malignant forms like choriocarcinoma.
2. Breast cancer: Pregnancy-associated breast cancer (PABC) is a type of breast cancer that occurs during pregnancy or within one year after delivery. It can be aggressive and challenging to diagnose due to the changes in the breast tissue during pregnancy.
3. Cervical cancer: Cervical cancer can occur during pregnancy, and its management depends on the stage of the disease and the gestational age. In some cases, treatment may need to be delayed until after delivery.
4. Lung cancer: Pregnancy does not increase the risk of lung cancer, but it can make diagnosis and treatment more challenging.
5. Melanoma: Melanoma is the most common malignant skin cancer during pregnancy. It can spread quickly and requires prompt treatment.

The management of neoplastic pregnancy complications depends on several factors, including the type and stage of the tumor, gestational age, and the patient's wishes. In some cases, surgery, chemotherapy, or radiation therapy may be necessary. However, these treatments can have potential risks to the developing fetus, so a multidisciplinary team of healthcare providers is often involved in the care of pregnant women with neoplastic complications.

Carcinoma, bronchogenic is a medical term that refers to a type of lung cancer that originates in the bronchi, which are the branching tubes that carry air into the lungs. It is the most common form of lung cancer and can be further classified into different types based on the specific cell type involved, such as squamous cell carcinoma, adenocarcinoma, or large cell carcinoma.

Bronchogenic carcinomas are often associated with smoking and exposure to environmental pollutants, although they can also occur in non-smokers. Symptoms may include coughing, chest pain, shortness of breath, wheezing, hoarseness, or unexplained weight loss. Treatment options depend on the stage and location of the cancer, as well as the patient's overall health and may include surgery, radiation therapy, chemotherapy, targeted therapy, or a combination of these approaches.

Hyperthyroidism is a medical condition characterized by an excessive production and release of thyroid hormones from the thyroid gland, leading to an increased metabolic rate in various body systems. The thyroid gland, located in the front of the neck, produces two main thyroid hormones: triiodothyronine (T3) and thyroxine (T4). These hormones play crucial roles in regulating many bodily functions, including heart rate, digestion, energy levels, and mood.

In hyperthyroidism, the elevated levels of T3 and T4 can cause a wide range of symptoms, such as rapid heartbeat, weight loss, heat intolerance, increased appetite, tremors, anxiety, and sleep disturbances. Some common causes of hyperthyroidism include Graves' disease, toxic adenoma, Plummer's disease (toxic multinodular goiter), and thyroiditis. Proper diagnosis and treatment are essential to manage the symptoms and prevent potential complications associated with this condition.

Vitamins are organic substances that are essential in small quantities for the normal growth, development, and maintenance of life in humans. They are required for various biochemical functions in the body such as energy production, blood clotting, immune function, and making DNA.

Unlike macronutrients (carbohydrates, proteins, and fats), vitamins do not provide energy but they play a crucial role in energy metabolism. Humans require 13 essential vitamins, which can be divided into two categories: fat-soluble and water-soluble.

Fat-soluble vitamins (A, D, E, and K) are stored in the body's fat tissues and liver, and can stay in the body for a longer period of time. Water-soluble vitamins (B-complex vitamins and vitamin C) are not stored in the body and need to be replenished regularly through diet or supplementation.

Deficiency of vitamins can lead to various health problems, while excessive intake of certain fat-soluble vitamins can also be harmful due to toxicity. Therefore, it is important to maintain a balanced diet that provides all the essential vitamins in adequate amounts.

Rickets is a medical condition characterized by the softening and weakening of bones in children, primarily caused by deficiency of vitamin D, calcium, or phosphate. It leads to skeletal deformities, bone pain, and growth retardation. Prolonged lack of sunlight exposure, inadequate intake of vitamin D-rich foods, or impaired absorption or utilization of vitamin D can contribute to the development of rickets.

"Intralesional injection" is a medical term that refers to the administration of a medication directly into a lesion or skin abnormality, such as a tumor, cyst, or blister. This technique is used to deliver the medication directly to the site of action, allowing for higher local concentrations and potentially reducing systemic side effects. Common examples include the injection of corticosteroids into inflamed tissues to reduce swelling and pain, or the injection of chemotherapeutic agents directly into tumors to shrink them.

A germ-line mutation is a genetic change that occurs in the egg or sperm cells (gametes), and thus can be passed down from parents to their offspring. These mutations are present throughout the entire body of the offspring, as they are incorporated into the DNA of every cell during embryonic development.

Germ-line mutations differ from somatic mutations, which occur in other cells of the body that are not involved in reproduction. While somatic mutations can contribute to the development of cancer and other diseases within an individual, they are not passed down to future generations.

It's important to note that germ-line mutations can have significant implications for medical genetics and inherited diseases. For example, if a parent has a germ-line mutation in a gene associated with a particular disease, their offspring may have an increased risk of developing that disease as well.

In the field of medicine, "time factors" refer to the duration of symptoms or time elapsed since the onset of a medical condition, which can have significant implications for diagnosis and treatment. Understanding time factors is crucial in determining the progression of a disease, evaluating the effectiveness of treatments, and making critical decisions regarding patient care.

For example, in stroke management, "time is brain," meaning that rapid intervention within a specific time frame (usually within 4.5 hours) is essential to administering tissue plasminogen activator (tPA), a clot-busting drug that can minimize brain damage and improve patient outcomes. Similarly, in trauma care, the "golden hour" concept emphasizes the importance of providing definitive care within the first 60 minutes after injury to increase survival rates and reduce morbidity.

Time factors also play a role in monitoring the progression of chronic conditions like diabetes or heart disease, where regular follow-ups and assessments help determine appropriate treatment adjustments and prevent complications. In infectious diseases, time factors are crucial for initiating antibiotic therapy and identifying potential outbreaks to control their spread.

Overall, "time factors" encompass the significance of recognizing and acting promptly in various medical scenarios to optimize patient outcomes and provide effective care.

Technetium Tc 99m Medronate is a radiopharmaceutical agent used in nuclear medicine for bone scintigraphy. It is a technetium-labeled bisphosphonate compound, which accumulates in areas of increased bone turnover and metabolism. This makes it useful for detecting and evaluating various bone diseases and conditions, such as fractures, tumors, infections, and arthritis.

The "Tc 99m" refers to the radioisotope technetium-99m, which has a half-life of approximately 6 hours and emits gamma rays that can be detected by a gamma camera. The medronate component is a bisphosphonate molecule that binds to hydroxyapatite crystals in bone tissue, allowing the radiolabeled compound to accumulate in areas of active bone remodeling.

Overall, Technetium Tc 99m Medronate is an important tool in nuclear medicine for diagnosing and managing various musculoskeletal disorders.

Radioimmunoassay (RIA) is a highly sensitive analytical technique used in clinical and research laboratories to measure concentrations of various substances, such as hormones, vitamins, drugs, or tumor markers, in biological samples like blood, urine, or tissues. The method relies on the specific interaction between an antibody and its corresponding antigen, combined with the use of radioisotopes to quantify the amount of bound antigen.

In a typical RIA procedure, a known quantity of a radiolabeled antigen (also called tracer) is added to a sample containing an unknown concentration of the same unlabeled antigen. The mixture is then incubated with a specific antibody that binds to the antigen. During the incubation period, the antibody forms complexes with both the radiolabeled and unlabeled antigens.

After the incubation, the unbound (free) radiolabeled antigen is separated from the antibody-antigen complexes, usually through a precipitation or separation step involving centrifugation, filtration, or chromatography. The amount of radioactivity in the pellet (containing the antibody-antigen complexes) is then measured using a gamma counter or other suitable radiation detection device.

The concentration of the unlabeled antigen in the sample can be determined by comparing the ratio of bound to free radiolabeled antigen in the sample to a standard curve generated from known concentrations of unlabeled antigen and their corresponding bound/free ratios. The higher the concentration of unlabeled antigen in the sample, the lower the amount of radiolabeled antigen that will bind to the antibody, resulting in a lower bound/free ratio.

Radioimmunoassays offer high sensitivity, specificity, and accuracy, making them valuable tools for detecting and quantifying low levels of various substances in biological samples. However, due to concerns about radiation safety and waste disposal, alternative non-isotopic immunoassay techniques like enzyme-linked immunosorbent assays (ELISAs) have become more popular in recent years.

Cholecalciferol is the chemical name for Vitamin D3. It is a fat-soluble vitamin that is essential for the regulation of calcium and phosphate levels in the body, which helps to maintain healthy bones and teeth. Cholecalciferol can be synthesized by the skin upon exposure to sunlight or obtained through dietary sources such as fatty fish, liver, and fortified foods. It is also available as a dietary supplement.

I believe there may be some confusion in your question as Polyethylenes are not a medical term, but rather a category of synthetic polymers commonly used in various industrial and medical applications. Here's a brief overview:

Polyethylene (PE) is a type of thermoplastic polymer made from the monomer ethylene. It is a versatile material with numerous applications due to its chemical resistance, durability, and flexibility. There are several types of polyethylenes, including:

1. Low-density polyethylene (LDPE): This type has a lower density and more branching in its molecular structure, which results in less crystallinity. LDPE is known for its flexibility and is often used in packaging films, bags, and containers.
2. High-density polyethylene (HDPE): HDPE has a higher density and less branching, resulting in greater crystallinity. It is more rigid than LDPE and is commonly used in applications such as bottles, pipes, and containers.
3. Linear low-density polyethylene (LLDPE): This type combines the flexibility of LDPE with some of the strength and rigidity of HDPE. LLDPE has fewer branches than LDPE but more than HDPE. It is often used in film applications, such as stretch wrap and agricultural films.
4. Ultra-high molecular weight polyethylene (UHMWPE): UHMWPE has an extremely high molecular weight, resulting in exceptional wear resistance, impact strength, and chemical resistance. It is commonly used in medical applications, such as orthopedic implants and joint replacements, due to its biocompatibility and low friction coefficient.

While polyethylenes are not a medical term per se, they do have significant medical applications, particularly UHMWPE in orthopedic devices.

An adenoma is a benign tumor that forms in glandular tissue. When referring to "acidophil," it describes the appearance of the cells under a microscope. Acidophils are cells that take up acidic dyes, giving them a distinct appearance. In the context of an adenoma, an acidophil adenoma would be a benign tumor composed of acidophil cells.

Acidophil adenomas are most commonly found in the pituitary gland and are also known as lactotroph or mammosomatotroph adenomas. These tumors can produce and release prolactin, growth hormone, or both, leading to various endocrine disorders such as hyperprolactinemia, acromegaly, or gigantism. Treatment options typically include surgical removal of the tumor or medical management with dopamine agonists or somatostatin analogs.

Postoperative complications refer to any unfavorable condition or event that occurs during the recovery period after a surgical procedure. These complications can vary in severity and may include, but are not limited to:

1. Infection: This can occur at the site of the incision or inside the body, such as pneumonia or urinary tract infection.
2. Bleeding: Excessive bleeding (hemorrhage) can lead to a drop in blood pressure and may require further surgical intervention.
3. Blood clots: These can form in the deep veins of the legs (deep vein thrombosis) and can potentially travel to the lungs (pulmonary embolism).
4. Wound dehiscence: This is when the surgical wound opens up, which can lead to infection and further complications.
5. Pulmonary issues: These include atelectasis (collapsed lung), pneumonia, or respiratory failure.
6. Cardiovascular problems: These include abnormal heart rhythms (arrhythmias), heart attack, or stroke.
7. Renal failure: This can occur due to various reasons such as dehydration, blood loss, or the use of certain medications.
8. Pain management issues: Inadequate pain control can lead to increased stress, anxiety, and decreased mobility.
9. Nausea and vomiting: These can be caused by anesthesia, opioid pain medication, or other factors.
10. Delirium: This is a state of confusion and disorientation that can occur in the elderly or those with certain medical conditions.

Prompt identification and management of these complications are crucial to ensure the best possible outcome for the patient.

The intraoperative period is the phase of surgical treatment that refers to the time during which the surgery is being performed. It begins when the anesthesia is administered and the patient is prepared for the operation, and it ends when the surgery is completed, the anesthesia is discontinued, and the patient is transferred to the recovery room or intensive care unit (ICU).

During the intraoperative period, the surgical team, including surgeons, anesthesiologists, nurses, and other healthcare professionals, work together to carry out the surgical procedure safely and effectively. The anesthesiologist monitors the patient's vital signs, such as heart rate, blood pressure, oxygen saturation, and body temperature, throughout the surgery to ensure that the patient remains stable and does not experience any complications.

The surgeon performs the operation, using various surgical techniques and instruments to achieve the desired outcome. The surgical team also takes measures to prevent infection, control bleeding, and manage pain during and after the surgery.

Overall, the intraoperative period is a critical phase of surgical treatment that requires close collaboration and communication among members of the healthcare team to ensure the best possible outcomes for the patient.

Osteoporosis is a systemic skeletal disease characterized by low bone mass, deterioration of bone tissue, and disruption of bone architecture, leading to increased risk of fractures, particularly in the spine, wrist, and hip. It mainly affects older people, especially postmenopausal women, due to hormonal changes that reduce bone density. Osteoporosis can also be caused by certain medications, medical conditions, or lifestyle factors such as smoking, alcohol abuse, and a lack of calcium and vitamin D in the diet. The diagnosis is often made using bone mineral density testing, and treatment may include medication to slow bone loss, promote bone formation, and prevent fractures.

Fibroblast Growth Factors (FGFs) are a family of growth factors that play crucial roles in various biological processes, including cell survival, proliferation, migration, and differentiation. They bind to specific tyrosine kinase receptors (FGFRs) on the cell surface, leading to intracellular signaling cascades that regulate gene expression and downstream cellular responses. FGFs are involved in embryonic development, tissue repair, and angiogenesis (the formation of new blood vessels). There are at least 22 distinct FGFs identified in humans, each with unique functions and patterns of expression. Some FGFs, like FGF1 and FGF2, have mitogenic effects on fibroblasts and other cell types, while others, such as FGF7 and FGF10, are essential for epithelial-mesenchymal interactions during organ development. Dysregulation of FGF signaling has been implicated in various pathological conditions, including cancer, fibrosis, and developmental disorders.

BCL-1 (B-cell leukemia/lymphoma 1) is not a gene itself but rather a chromosomal translocation that results in the formation of an abnormal fusion gene. The BCL-1 translocation, also known as t(14;18)(q32;q21), is most commonly found in follicular lymphoma, a type of slow-growing non-Hodgkin lymphoma.

The BCL-1 translocation involves the juxtaposition of the BCL-2 gene, which is located on chromosome 18, with the IGH (immunoglobulin heavy chain) gene, which is located on chromosome 14. This translocation results in the overexpression of the BCL-2 protein, which inhibits apoptosis or programmed cell death. The overexpression of BCL-2 leads to the accumulation of cancer cells and contributes to the development and progression of follicular lymphoma.

It is important to note that while BCL-1 is a chromosomal translocation, it can also refer to the protein encoded by the BCL-2 gene when it is overexpressed due to the t(14;18) translocation. In this context, BCL-1 is considered a proto-oncogene because its overexpression promotes cancer development and progression.

Exostoses are benign (noncancerous) bone growths that develop on the surface of a bone, usually in response to repeated stress or friction. They are often small and smooth, but can become larger and more irregular over time. In some cases, they may cause pain or discomfort, especially if they continue to grow and put pressure on nearby nerves, muscles, or other bones.

Exostoses can occur in various parts of the body, but they are most commonly found in the long bones of the arms and legs, as well as in the small bones of the feet. They may also develop in response to chronic irritation or injury, such as from jogging or playing sports that involve a lot of running or jumping.

In some cases, exostoses may be surgically removed if they cause persistent pain or other symptoms. However, in many cases, they do not require treatment and can be left alone. If you are concerned about any bone growths or other unusual symptoms, it is always best to consult with a healthcare professional for an accurate diagnosis and treatment plan.

Nephrectomy is a surgical procedure in which all or part of a kidney is removed. It may be performed due to various reasons such as severe kidney damage, kidney cancer, or living donor transplantation. The type of nephrectomy depends on the reason for the surgery - a simple nephrectomy involves removing only the affected portion of the kidney, while a radical nephrectomy includes removal of the whole kidney along with its surrounding tissues like the adrenal gland and lymph nodes.

The "subtraction technique" is not a widely recognized or established term in medical terminology. It may refer to various methods used in different medical contexts that involve subtracting or comparing measurements, values, or observations to diagnose, monitor, or treat medical conditions. However, without more specific context, it's difficult to provide an accurate medical definition of the term.

In radiology, for example, the subtraction technique is a method used in imaging to enhance the visibility of certain structures by digitally subtracting one image from another. This technique is often used in angiography to visualize blood vessels more clearly.

Therefore, it's essential to provide more context or specify the medical field when using the term "subtraction technique" to ensure accurate communication and understanding.

Biochemical confirmation of primary hyperparathyroidism is following by investigations to localize the culprit lesion. Primary ... Primary hyperparathyroidism (or PHPT) is a medical condition where the parathyroid gland (or a benign tumor within it) produce ... The diagnosis of primary hyperparathyroidism is made by blood tests.[citation needed] Serum calcium levels are usually elevated ... The most common cause of primary hyperparathyroidism is a sporadic, single parathyroid adenoma resulting from a clonal mutation ...
Both primary and secondary may result in osteoporosis (weakening of the bones). In 80% of cases, primary hyperparathyroidism is ... The diagnosis of primary hyperparathyroidism is made by finding elevated calcium and PTH in the blood. Primary ... In primary hyperparathyroidism, about 75% of people are "asymptomatic". While most primary patients are asymptomatic at the ... In cases of primary hyperparathyroidism or tertiary hyperparathyroidism, heightened PTH leads to increased serum calcium ( ...
Hyperparathyroidism Primary hyperparathyroidism Secondary hyperparathyroidism Pitt SC, Sippel RS, Chen H (October 2009). " ... in the parathyroid glands resulting in primary hyperparathyroidism. While primary hyperparathyroidism is the most common form ... Tertiary hyperparathyroidism shares many symptomatic features with that of primary hyperparathyroidism, as the two are defined ... Unlike primary hyperparathyroidism, the tertiary form presents as a progressive stage of resolved secondary hyperparathyroidism ...
Primary hyperparathyroidism Tertiary hyperparathyroidism Robbins and Cotran pathologic basis of disease. Kumar, Vinay, 1944-, ... Both processes lead to hypocalcemia and hence secondary hyperparathyroidism. Secondary hyperparathyroidism can also result from ... In contrast with secondary hyperparathyroidism, tertiary hyperparathyroidism is associated with hypercalcemia rather than ... but many will continue to have a degree of residual hyperparathyroidism (tertiary hyperparathyroidism) post-transplant with ...
Insogna, Karl (September 13, 2018). "Primary Hyperparathyroidism". New England Journal of Medicine. 379 (11): 1050-1059. doi: ... Shandling suffered from hyperparathyroidism, a serious disease which often goes undiagnosed or untreated. If left untreated, it ...
Insogna, Karl (September 13, 2018). "Primary Hyperparathyroidism". New England Journal of Medicine. 379 (11): 1050-1059. doi: ...
Insogna, Karl (September 13, 2018). "Primary Hyperparathyroidism". New England Journal of Medicine. 379 (11): 1050-1059. doi: ...
Primary hyperparathyroidism is relatively more common in postmenopausal women. The primary treatment for this disease is the ... Most experts believe that Sensipar should not be used for patients with primary hyperparathyroidism (patients that have a high ... Tertiary hyperparathyroidism develops when the hyperplastic gland of secondary hyperparathyroidism constantly releases PTH, ... Primary hyperparathyroidism happens when the normal mechanism of regulation by negative feedback of calcium is interrupted, or ...
individuals with primary hyperparathyroidism. individuals being monitored to assess the response or efficacy of an approved ... The risk factors for low bone density and primary considerations for a bone density test include: females age 65 or older. ... hyperparathyroidism, or alcoholism. To prevent low bone density it is recommended to have sufficient calcium and vitamin D. ...
The main indication for parathyroidectomy is primary hyperparathyroidism, a condition in which one or more of the parathyroid ... Not all cases of primary hyperparathyroidism require surgery, but it is recommended if the condition causes significant ... Augustine, MM; Bravo, PE; Zeiger, MA (Mar-Apr 2011). "Surgical treatment of primary hyperparathyroidism". Endocrine Practice. ... "The American Association of Endocrine Surgeons Guidelines for Definitive Management of Primary Hyperparathyroidism". JAMA ...
Halabé, A.; Sutton, R. A. (1987). "Primary hyperparathyroidism and idiopathic hypercalciuria". Mineral and Electrolyte ... If blood calcium levels are normal, which can rule out hyperparathyroidism, treatment would begin with adopting a diet of ~800 ... IH shares many similarities with hyperparathyroidism, a condition associated with the elevated release of parathyroid hormone ... Sella, Stefania; Cattelan, Catia; Realdi, Giuseppe; Giannini, Sandro (2008). "Bone disease in primary hypercalciuria". Clinical ...
Cope, also described primary hyperplasia of the parathyroid glands as a cause for hyperparathyroidism, as distinct from ... Parathyroidectomy is now a part of the standard management of cases of primary hyperparathyroidism. The management of burns, ... CASTLEMAN B, COPE O (October 1951). "Primary parathyroid hypertrophy and hyperplasia; a review of 11 cases at the Massachusetts ... Churchill ED, Cope O (July 1936). "The Surgical Treatment of Hyperparathyroidism". Ann. Surg. 104 (1): 9-35. doi:10.1097/ ...
Primary hyperparathyroidism has to be excluded. Diagnosis is made by looking at past medical history and laboratory studies.[ ... Normal vitamin D levels eliminate primary hypercalcemia. Electrocardiograms (ECG): An ECG can also be used to diagnose MAS. The ... Low serum PTH levels also exclude primary hyperthyroidism. Phosphorus: low serum phosphorus levels due to low PTH. Creatinine ... Sources of calcium and alkali include dietary supplements taken for the prevention of osteoporosis or hyperparathyroidism and ...
Coe FL (August 1974). "Magnitude of metabolic acidosis in primary hyperparathyroidism". Arch. Intern. Med. 134 (2): 262-5. doi: ... Patients with hyperparathyroidism may have a lower than normal pH, slightly decreased PaCO2 due to respiratory compensation, a ... an abnormal connection between the pancreas and duodenum Spironolactone High ostomy output Hyperparathyroidism - can cause ...
Vaizey CJ, Ali M, Gilbert JM (June 1997). "Chronic parathyroiditis associated with primary hyperplastic hyperparathyroidism". J ... It can be associated with hyperparathyroidism, though most cases are asymptomatic. ...
Primary treatment of hypercalcemia consists of administering IV fluids. If the hypercalcemia is severe and/or associated with ... Hyperparathyroidism and malignancy are the predominant causes. It can also be caused by muscle cell breakdown, prolonged ... Part of the danger of hyperkalemia is that it is often asymptomatic, and only detected during normal lab work done by primary ... The most common causes of hypercalcemia are certain types of cancer, hyperparathyroidism, hyperthyroidism, pheochromocytoma, ...
This may be mistaken for primary hyperparathyroidism. However, evaluation of urine calcium level will reveal a low level of ... If urine calcium is not checked, this may lead to parathyroidectomy for presumed primary hyperparathyroidism Additionally as ... As a consequence, these individuals are not at increased risk of the complications of hyperparathyroidism.[citation needed] ...
Cardiomegaly Primary hyperparathyroidism Ventricular hypertrophy Maron, Barry J; Maron, Martin S (2013-01-19). "Hypertrophic ... Primary disease of the muscle of the heart that cause LVH are known as hypertrophic cardiomyopathies, which can lead into heart ... and some primary diseases of the muscle of the heart.[citation needed] Causes of increased afterload that can cause LVH include ...
Walker RP, Paloyan E, Gopalsami C (2004). "Symptoms in patients with primary hyperparathyroidism: muscle weakness or sleepiness ... Hyperparathyroidism Zimmermann E, Wassmer S, Steudle V (1996). "Long-term treatment with calcium-alpha-ketoglutarate corrects ... patients with Hyperparathyroidism have been shown to benefit from Calcium-alpha-ketoglutarate by reducing elevated ...
"Cardiovascular manifestations of primary hyperparathyroidism: a narrative review". European Journal of Endocrinology. 177 (6): ...
In primary hyperparathyroidism, one or more of the four parathyroid glands either develops a benign tumor called an adenoma or ... Sestamibi is mainly used to image the myocardium (heart muscle). It is also used in the work-up of primary hyperparathyroidism ... This imaging method will detect 75 to 90 percent of abnormal parathyroid glands in primary hyperparathyroidism. An endocrine ... "Minimally invasive radio-guided surgery for primary hyperparathyroidism". Annals of Surgical Oncology. 14 (12): 3401-3402. doi: ...
Geelhoed, GW; Kelly, TR (December 1989). "Pseudogout as a clue and complication in primary hyperparathyroidism". Surgery. 106 ( ... Tissue damage Hyperparathyroidism Hypercalcemia Hyperphosphatemia Calcium oxalate deposition: Enhanced production of oxalic ... Septic arthritis Type IIa hyperlipoproteinemia Amyloidosis Multicentric reticulohistiocytosis Hyperparathyroidism ... in kidney failure Excessive ascorbic acid intake in kidney failure Obesity Kidney failure Hyperphosphatemia Hyperparathyroidism ...
After recognition, primary hyperparathyroidism should be proved or excluded. In extreme cases of primary hyperparathyroidism, ... Primary hyperparathyroidism Solitary parathyroid adenoma Primary parathyroid hyperplasia Parathyroid carcinoma Multiple ... Primary hyperparathyroidism occurs in 1-7 per 1,000 people, and hypercalcaemia occurs in about 2.7% of those with cancer. The ... Most outpatient cases are due to primary hyperparathyroidism and inpatient cases due to cancer. Other causes of hypercalcemia ...
... "primary hyperparathyroidism without cancer", "cancer without primary hyperparathyroidism" as well as "combined primary ... This confers a likelihood ratio positive of 7 for primary hyperparathyroidism. The probability of primary hyperparathyroidism ... This corresponds to a probability of primary hyperparathyroidism (PH) in the population of: Pr ( PH in population ) = 0.5 years ... The main causes of hypercalcemia are primary hyperparathyroidism (PH) and cancer, so for simplicity, the list of candidate ...
... can also be used to treat severe hypercalcemia in patients with primary hyperparathyroidism who are unable to ... the treatment of parathyroid carcinoma and primary hyperparathyroidism in adults. the reduction of hypercalcaemia in adults ... and primary hyperparathyroidism. Cinacalcet acts as a calcimimetic (i.e., it mimics the action of calcium on tissues) by ... the treatment of secondary hyperparathyroidism (HPT) in children aged three years and older with end stage renal disease (ESRD ...
Calcium also acts as one of the primary regulators of osmotic stress (osmotic shock). Chronically elevated plasma calcium ( ... One cause of hypercalcemia is a condition known as hyperparathyroidism. Some invertebrates use calcium compounds for building ... "Serum ionized calcium and corrected total calcium in borderline hyperparathyroidism". Clin. Chem. 24 (11): 1962-65. doi:10.1093 ...
Primary Benign Hyperparathyroidism and Secondary Hyperparathyroidism". Endocrine Abstracts. Bioscientifica. 56. doi:10.1530/ ... Parathyroid carcinoma is sometimes diagnosed during surgery for primary hyperparathyroidism. If the surgeon suspects carcinoma ... autosomal dominant familial isolated hyperparathyroidism and hyperparathyroidism-jaw tumor syndrome (which also is hereditary ... parathyroid scintigraphy between benign and malignant parathyroid lesions in patients with primary hyperparathyroidism". ...
In MEN2A, primary hyperparathyroidism occurs in 10-50% of cases and is usually diagnosed after the third decade of life. Rarely ... Occasionally pheochromocytoma or primary hyperparathyroidism may be the initial diagnosis.[citation needed] Pheochromocytoma ... of cases and with primary hyperparathyroidism in 5-20% of cases.[citation needed] MEN2B associates medullary thyroid carcinoma ... when both glands are involved and selective resection of pathologic parathyroid glands for primary hyperparathyroidism. ...
P-glycoprotein expression is associated with sestamibi washout in primary hyperparathyroidism. British Journal of Surgery, 2007 ... P-glycoprotein expression in primary breast cancer detected by immunocytochemistry with two monoclonal antibodies. Br J Cancer ... P-glycoprotein expression in primary breast cancer detected by immunocytochemistry with two monoclonal antibodies. Br J Cancer ...
"What Symptom Improvement Can Be Expected After Operation for Primary Hyperparathyroidism?". World Journal of Surgery. 33 (11): ... Caron, Nadine R.; Sturgeon, Cord; Clark, Orlo H. (August 2004). "Persistent and recurrent hyperparathyroidism". Current ... A Case Study of Enhanced Skills for Rural Primary Care providers". Canadian Medical Education Journal. 3 (1): e33-e41. doi: ...
Biochemical confirmation of primary hyperparathyroidism is following by investigations to localize the culprit lesion. Primary ... Primary hyperparathyroidism (or PHPT) is a medical condition where the parathyroid gland (or a benign tumor within it) produce ... The diagnosis of primary hyperparathyroidism is made by blood tests.[citation needed] Serum calcium levels are usually elevated ... The most common cause of primary hyperparathyroidism is a sporadic, single parathyroid adenoma resulting from a clonal mutation ...
Hyperparathyroidism is a disease characterized by excessive secretion of parathyroid hormone, an 84-amino acid polypeptide ... Primary Hyperparathyroidism. Definition of problem. Primary hyperparathyroidism is the unregulated overproduction of ... Hyperparathyroidism is usually subdivided into primary, secondary, and tertiary hyperparathyroidism.. Signs and symptoms of ... What causes hypercalcemia in primary hyperparathyroidism?. What is the role of lab studies in the evaluation of primary ...
Hyperparathyroidism is a disease characterized by excessive secretion of parathyroid hormone, an 84-amino acid polypeptide ... Primary Hyperparathyroidism. Definition of problem. Primary hyperparathyroidism is the unregulated overproduction of ... Hyperparathyroidism is usually subdivided into primary, secondary, and tertiary hyperparathyroidism.. Signs and symptoms of ... What causes hypercalcemia in primary hyperparathyroidism?. What is the role of lab studies in the evaluation of primary ...
Primary hyperparathyroidism, familial hypocalciuric hypercalcemia, familial hyperparathyroidism, and secondary ... Primary hyperparathyroidism most commonly causes hypercalcemia in the outpatient setting. These two account for over 90% ... We report the rare case of a patient with hypercalcemia and diagnosed primary hyperparathyroidism. The patient had persistent ... production of humoral factors by the primary tumor also known as humoral hypercalcemia of malignancy that accounts for about 80 ...
Parathyroidectomy for adults with primary hyperparathyroidism. What is primary hyperparathyroidism?. Primary ... Primary hyperparathyroidism (PHPT), a disorder in which the parathyroid glands produce excessive amounts of parathyroid hormone ... Parathyroidectomy for adults with primary hyperparathyroidism. Cochrane Database of Systematic Reviews 2023, Issue 3. Art. No ... Our primary outcomes were 1. cure of PHPT, 2. morbidity related to PHPT and 3. serious adverse events. Our secondary outcomes ...
... Otolaryngol Head Neck Surg. 1997 ...
The most common problem related to the parathyroid glands is primary hyperparathyroidism (PTH). This occurs when one or more ... However, primary hyperparathyroidism occurs when one or more parathyroid glands become enlarged and independently produce ... The most common problem related to the parathyroid glands is primary hyperparathyroidism (PTH). This occurs when one or more ...
Hyperparathyroidism primary. Definition: Hyperfunction of the parathyroid glands resulting in the overproduction of parathyroid ... Synonyms (terms occurring on more labels are shown first): primary hyperparathyroidism More information: PubMed search and ...
Biochemical signs and severity of symptoms of primary hyperparathyroidism (pHPT) differ among patients, and little is known of ... Biochemical signs and severity of symptoms of primary hyperparathyroidism (pHPT) differ among patients, and little is known of ... Parathyroid MEN1 gene mutations in relation to clinical characteristics of nonfamilial primary hyperparathyroidism. *Mark ... Biochemical signs and severity of symptoms of primary hyperparathyroidism (pHPT) differ among patients, and little is known of ...
Primary hyperparathyroidism develops infrequently in dogs, but it should remain a primary differential diagnosis in patients ... The hallmark for primary hyperparathyroidism is persistent progressive hypercalcemia. In dogs with confirmed primary ... A challenging case: Primary hyperparathyroidism in a dog. Aug 1, 2009. Michael R. Goldstein, DVM ... Primary hyperparathyroidism in 29 dogs: diagnosis, treatment, outcome and associated renal failure. J Small Anim Pract 2005;46( ...
Primary hyperparathyroidism, thyroid disorders, surgical treatment, papillary thyroid cancer ... Keywords : Primary hyperparathyroidism, thyroid disorders, surgical treatment, papillary thyroid cancer Read: 1920 Downloads: ... Objective: The relationship between primary hyperparathyroidism (pHPT) and papillary thyroid cancer (PTC) still remains unclear ... Incidental Finding of Papillary Thyroid Carcinoma in the Patients with Primary Hyperparathyroidism. ...
Trabecular bone score is negatively associated with bone resorbtion markers in patients with primary hyperparathyroidism. ... Objectives: Mean TBS (Trabecular Bone Score) values are generally lower in PHPT (primary hyperparathyroidism) patients than ... Trabecular bone score is negatively associated with bone resorbtion markers in patients with primary hyperparathyroidism (. ... Trabecular bone score is negatively associated with bone resorbtion markers in patients with primary hyperparathyroidism ...
Dive into the research topics of Presentation, diagnostic assessment and surgical outcomes in primary hyperparathyroidism: a ... Presentation, diagnostic assessment and surgical outcomes in primary hyperparathyroidism: a single centres experience. ...
... and bone mineral measurements of 65 patients with primary hyperparathyroidism are reviewed. Fifty per cent presented with renal ... Pre- and postoperative bone metabolism of primary hyperparathyroidism. S.Suzuki, T.Fukushima, H.Ami, S.Asahi, H.Onogi, I. ... Musculoskeletal manifestations of primary hyperparathyroidism. RameshPappu, Serge A.Jabbour, Antonio MRegianto, Antonio J. ... Longitudinal changes in forearm bone mineral content in primary hyperparathyroidism. J.Warner, P.Clifton-Bligh, S.Posen, A. ...
... hyperparathyroidism). Explore symptoms, inheritance, genetics of this condition. ... Familial isolated hyperparathyroidism is an inherited condition characterized by overactivity of the parathyroid glands ( ... familial isolated hyperparathyroidism is considered a form of primary hyperparathyroidism.. Disruption of the normal calcium ... Familial isolated primary hyperparathyroidism caused by mutations of the MEN1 gene. Nat Clin Pract Endocrinol Metab. 2008 Jan;4 ...
How is primary hyperparathyroidism treated?. Medical treatment. There was in the past no effective medical treatment to control ... This is the best form of treatment for primary hyperparathyroidism. The essential principle is to remove the parathyroid gland ... The medical treatment of primary hyperparathyroidism has recently been reviewed ( Khan et al February 2009 Journal Clinical ... 1. Long term bisphosphonates therapy may increase bone strength in untreated primary hyperparathyroidism. There is at the ...
Relationship between bone turnover and left ventricular function in primary hyperparathyroidism. Title: Relationship between ... Relationship between bone turnover and left ventricular function in primary hyperparathyroidism. *Login ... "Eplerenone in Primary Hyperparathyroidism" (EPATH) Trial. Multivariate linear regression analyses with LV ejection fraction ( ... that circulating markers of bone turnover correlate with LV function in a cohort of patients with primary hyperparathyroidism ( ...
Thiazides may be a safe and effective treatment alternative for patients with primary hyperparathyroidism when surgery is not ... Asymptomatic primary hyperparathyroidism (PHPT) is a common disorder for which surgery is the only definitive therapy. ... Thiazide Treatment in Primary Hyperparathyroidism. A New Indication for an Old Medication?. ... Context: There is no therapy for control of hypercalciuria in nonoperable patients with primary hyperparathyroidism (PHPT). ...
Primary hyperparathyroidism. Depending on your age, kidney function, and bone effects, you might need surgery to remove the ... Hyperparathyroidism occurs when one or more of your parathyroid glands becomes overly active and releases too much PTH. This ... Hyperparathyroidism. The parathyroid glands are four small glands located behind the thyroid gland in the neck. They control ... Hyperparathyroidism can affect your blood calcium levels and cause other health problems. Learn the causes, types, ...
... Short summary The purpose of this project is to examine, ... Primary hyperparathyroidism (pHPT) is an endocrinological disorder in which plasma calcium levels are abnormally high due to an ... Patients 18 years and older with primary hyperparathyroidism referred to the Department of Otorhinolaryngology, Head and Neck ... used to localise pathological parathyroid glands prior to surgical removal in patients with primary hyperparathyroidism. \n. ...
Hyperparathyroidism is a disease characterized by excessive secretion of parathyroid hormone, an 84-amino acid polypeptide ... Primary Hyperparathyroidism. Definition of problem. Primary hyperparathyroidism is the unregulated overproduction of ... Unlike primary hyperparathyroidism, medical management is the mainstay of treatment for secondary hyperparathyroidism. ... Management of Primary Hyperparathyroidism: Can We Do Better?. Am Surg. 2017 Jan 1. 83 (1):64-70. [QxMD MEDLINE Link]. ...
Together, they explore a new JCEM article focused on care gaps in the management of patients with hyperparathyroidism. ... "Systems-Level Opportunities in the Management of Primary Hyperparathyroidism: An Informatics-Based Assessment." ... EFL038 - Aldosterone-to-Renin Ratio Variability in Primary Aldosteronism * EFL037 - Predicting HPA Function After Pituitary ... clinical work is predominantly in the area of metabolic bone disease with an emphasis on osteoporosis and hyperparathyroidism. ...
1.1 Secondary Hyperparathyroidism 1.2 Parathyroid Carcinoma 1.3 Primary Hyperparathyroidism 2 DOSAGE AND ADMINISTRATION 2.1 ... 1.3 Primary Hyperparathyroidism. Cinacalcet tablets are indicated for the treatment of severe hypercalcemia in adult patients ... 14.3 Patients with Hypercalcemia Due to Primary Hyperparathyroidism 16 HOW SUPPLIED/STORAGE AND HANDLING 17 PATIENT COUNSELING ... Table 3. Adverse Reactions with Frequency ≥10% in a Single Arm, Open-Label Study in Patients with Primary Hyperparathyroidism ...
How is primary hyperparathyroidism diagnosed?. The diagnosis is made by proving the biochemical abnormality. ... allowing the experienced clinician to differentiate it from primary hyperparathyroidism.. Before any surgery is performed, if ... assays are discriminating and there are few situations where a raised PTH does not indicate true primary hyperparathyroidism. ...
We report a patient with neonatal primary hyperparathyroidism who survived without fractures or parathyroidectomy to an age of ... D deficiency represents a unique combination of metabolic abnormalities in a patient with neonatal primary hyperparathyroidism. ... Neonatal primary hyperparathyroidism is a life threatening disorder that is associated with severe hypercalcaemia, hypotonia, ... Neonatal primary hyperparathyroidism masked by vitamin D deficiency. Meeran K., Husain M., Puccini M., Scott H., Dionisi-Vici C ...
Irisin and parathyroid hormone are linked in primary hyperparathyroidism. Irisin is considered a molecule with hormone function ... Moreover, as second step, they found that in patients affected by primary hyperparathyroidism condition (having chronic high ... such as primary hyperparathyroidism, the prolonged action of elevated pathological PTH blood levels causes a BMD reduction. In ...
Primary hyperparathyroidism (PHPT) is a rare disorder in pediatric age, with an estimated incidence of 2-5 cases in 100,000 ... hyperparathyroidism caused by a parathyroid adenoma can disrupt the balance of calcium and phosphate in the body, leading to ... parathyroid adenomas causing hyperparathyroidism can lead to skeletal deformities, such as bowing of the long bones or other ... abnormalities, resembling the bone deformities seen in rickets; 3) growth delay: hyperparathyroidism resulting from a ...
Robotic surgery for primary hyperparathyroidism. / Karagkounis, Georgios; Uzun, Duygu Derya; Mason, David P. et al. In: ... Robotic surgery for primary hyperparathyroidism. Georgios Karagkounis, Duygu Derya Uzun, David P. Mason, Sudish C. Murthy, Eren ... Karagkounis G, Uzun DD, Mason DP, Murthy SC, Berber E. Robotic surgery for primary hyperparathyroidism. Surgical endoscopy. ... Robotic surgery for primary hyperparathyroidism. In: Surgical endoscopy. 2014 ; Vol. 28, No. 9. pp. 2702-2707. ...
All rights reserved.. Primary hyperparathyroidism (PHPT) may occur as part of a complex syndrome or as an isolated (non- ... Non-syndromic PHPT, which may be familial and referred to as familial isolated hyperparathyroidism (FIHP), may also be due to ... Syndromic forms of PHPT include multiple endocrine neoplasia (MEN) types 1 to 4 (MEN1 to MEN4), and the hyperparathyroidism-jaw ... All rights reserved.. Primary hyperparathyroidism (PHPT) may occur as part of a complex syndrome or as an isolated (non- ...
title = "Primary hyperparathyroidism and ALS is there a relation?",. abstract = "Background: An association between primary ... Primary hyperparathyroidism and ALS is there a relation?. Carlayne E. Jackson, A. A. Amato, W. W. Bryan, G. I. Wolfe, K. ... Primary hyperparathyroidism and ALS is there a relation? / Jackson, Carlayne E.; Amato, A. A.; Bryan, W. W. et al. In: ... Primary hyperparathyroidism and ALS is there a relation? Neurology. 1998 Jun;50(6):1795-1799. doi: 10.1212/WNL.50.6.1795 ...
  • Primary hyperparathyroidism (or PHPT) is a medical condition where the parathyroid gland (or a benign tumor within it) produce excess amounts of parathyroid hormone (PTH). (wikipedia.org)
  • In order to diagnose normocalcemic PHPT, ionized calcium levels should be normal, and all secondary causes for secondary hyperparathyroidism (such as vitamin D deficiency and chronic kidney disease) ruled out. (wikipedia.org)
  • Primary hyperparathyroidism (PHPT) is a disorder in which the parathyroid glands (four glands located near or on the thyroid in the neck) become enlarged and produce too much parathyroid hormone. (cochrane.org)
  • Biochemical signs and severity of symptoms of primary hyperparathyroidism (pHPT) differ among patients, and little is known of any coupling of clinical characteristics of nonfamilial pHPT to genetic abnormalities in the parathyroid tumors. (lu.se)
  • The relationship between primary hyperparathyroidism (pHPT) and papillary thyroid cancer (PTC) still remains unclear. (eajm.org)
  • Objectives: Mean TBS (Trabecular Bone Score) values are generally lower in PHPT (primary hyperparathyroidism) patients than controls. (endocrine-abstracts.org)
  • We therefore aimed to test the hypothesis that circulating markers of bone turnover correlate with LV function in a cohort of patients with primary hyperparathyroidism (pHPT). (fu-berlin.de)
  • Cross-sectional data of 155 subjects with pHPT were analyzed who participated in the "Eplerenone in Primary Hyperparathyroidism" (EPATH) Trial. (fu-berlin.de)
  • There is no therapy for control of hypercalciuria in nonoperable patients with primary hyperparathyroidism (PHPT). (medscape.com)
  • Asymptomatic primary hyperparathyroidism (PHPT) is a common disorder for which surgery is the only definitive therapy. (medscape.com)
  • Primary hyperparathyroidism (pHPT) is an endocrinological disorder in which plasma calcium levels are abnormally high due to an autonomous overproduction of parathyroid hormone by one or more of the four parathyroid glands. (rsyd.dk)
  • Primary hyperparathyroidism (PHPT) is a rare disorder in pediatric age, with an estimated incidence of 2-5 cases in 100,000 live births. (panafrican-med-journal.com)
  • Importance Emerging computed tomographic (CT) imaging techniques for the localization of primary hyperparathyroidism (PHPT) may be superior to the current imaging standard, thus necessitating a critical review and pooling of available evidence.Objective Primary hyperparathyroidism requires accurate imaging to guide definitive surgical management. (ochsner.org)
  • The association between pancreatitis (PTS) and primary hyperparathyroidism (PHPT) has been previously reported in a few case studies. (ispub.com)
  • An interesting case of persistent hypercalcaemia of primary hyperparathyroidism (pHPT) resistant to medical management for more than 5 years, who demonstrated a dramatic response to the first dose of denosumab with a significant and persistent drop in her level of calcium, from a baseline of 3 mmol/l to 2.7 mmol/l over a period of 9 months. (touchendocrinology.com)
  • Introduction: Primary hyperparathyroidism (PHPT) occurs as part of familial syndromes, including CDC73-related disorders caused by germline pathogenic variants of the CDC73 gene, particularly in early adulthood. (elsevierpure.com)
  • Context: Primary hyperparathyroidism (PHPT) and sarcoidosis may separately contribute to abnormal calcium and phosphate metabolism via different mechanisms, and their coexistence is infrequently reported. (elsevierpure.com)
  • To formulate clinical consensus recommendations on the presentation, assessment, and management of primary hyperparathyroidism (PHPT) in adults. (austin.org.au)
  • Primary hyperparathyroidism is most commonly due to solitary parathyroid adenoma. (wikipedia.org)
  • Primary hyperparathyroidism with an adenoma or hyperplasia producing hypercalcemia is a relatively common endocrine problem that is treated surgically. (hindawi.com)
  • In approximately 85% of cases, primary hyperparathyroidism is caused by a single adenoma. (medscape.com)
  • 5) electrolyte imbalances: hyperparathyroidism caused by a parathyroid adenoma can disrupt the balance of calcium and phosphate in the body, leading to abnormal serum levels. (panafrican-med-journal.com)
  • 5. Shimizu H, Kodama A. Severe acute pancreatitis as a first symptom of primary hyperparathyroid adenoma: a case report. (ispub.com)
  • In approximately 85-90% of cases, primary hyperparathyroidism is caused by a single adenoma. (medscape.com)
  • The signs and symptoms of primary hyperparathyroidism are those of hypercalcemia. (wikipedia.org)
  • Primary hyperparathyroidism most commonly causes hypercalcemia in the outpatient setting. (hindawi.com)
  • Several mechanisms lead to hypercalcemia in malignancy-direct osteolysis by metastatic disease or, more commonly, production of humoral factors by the primary tumor also known as humoral hypercalcemia of malignancy that accounts for about 80% of malignancy-related hypercalcemia. (hindawi.com)
  • We report the rare case of a patient with hypercalcemia and diagnosed primary hyperparathyroidism. (hindawi.com)
  • Differential diagnoses for the dog's hypercalcemia included lymphoma, leukemia, multiple myeloma, primary hyperparathyroidism, and, less likely, excessive vitamin D consumption (because of the normal vitamin D concentration). (dvm360.com)
  • In familial isolated hyperparathyroidism, one or more overactive parathyroid glands release excess parathyroid hormone, which causes the levels of calcium in the blood to rise (hypercalcemia). (medlineplus.gov)
  • Often, the first indication of the condition is elevated calcium levels identified through a routine blood test, even though the affected individual may not yet have signs or symptoms of hyperparathyroidism or hypercalcemia. (medlineplus.gov)
  • Familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism also belong to this category. (medscape.com)
  • Severe hypercalcemia in adult patients with primary HPT who are unable to parathyroidectomy. (nih.gov)
  • Primary hyperparathyroidism usually presents as an incidental finding of asymptomatic hypercalcemia on a chemistry panel. (aafp.org)
  • The diagnosis of primary hyperparathyroidism is made when hypercalcemia and elevated PTH levels are present. (medscape.com)
  • Hyperparathyroidism is usually subdivided into primary, secondary, and tertiary hyperparathyroidism. (medscape.com)
  • Patients with secondary hyperparathyroidism usually have low-normal calcium and elevated parathyroid hormone. (medscape.com)
  • Unlike primary hyperparathyroidism, medical management is the mainstay of treatment for secondary hyperparathyroidism. (medscape.com)
  • Secondary Hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on dialysis. (nih.gov)
  • In patients with hyperparathyroidism due to renal failure (a type of secondary hyperparathyroidism) all parathyroid glands are typically overactive. (ahns.info)
  • [ 4 ] Rarely, patients develop hyperparathyroidism secondary to a parathyroid carcinoma . (medscape.com)
  • Introduction and Objective: To report a case of a patient with secondary hyperparathyroidism that developed brown tumour in bilateral maxilla surgically managed with bilateral osteoplasty for aesthetic reasons. (bvsalud.org)
  • Conclusion: Secondary hyperparathyroidism related with oral brown tumour is a rare condition that affects function and aesthetic. (bvsalud.org)
  • Both processes lead to hypocalcaemia and secondary hyperparathyroidism 3 . (bvsalud.org)
  • This guideline covers the assessment, investigation and management of tinnitus in primary, community and secondary care. (bvsalud.org)
  • A low plasma bicarbonate (HCO3-) concentration represents, by definition, metabolic acidosis, which may be primary or secondary to a respiratory alkalosis. (medscape.com)
  • Patients 18 years and older with primary hyperparathyroidism referred to the Department of Otorhinolaryngology, Head and Neck Surgery at Odense University Hospital for parathyroidectomy. (rsyd.dk)
  • We report a patient with neonatal primary hyperparathyroidism who survived without fractures or parathyroidectomy to an age of nine months, and in whom the hypercalcaemia became masked by vitamin D deficiency. (ox.ac.uk)
  • An absence of skeletal complications, a survival beyond three months of age without parathyroidectomy and the masking of the hypercalcaemia by vitamin D deficiency represents a unique combination of metabolic abnormalities in a patient with neonatal primary hyperparathyroidism. (ox.ac.uk)
  • Background: Open cervical parathyroidectomy is the standard of care for the treatment of primary hyperparathyroidism (PHP). (elsevierpure.com)
  • Parathyroidectomy is the definitive treatment for primary hyperparathyroidism. (aafp.org)
  • Parathyroid surgery (or parathyroidectomy) is the main treatment for patients with primary hyperparathyroidism. (ahns.info)
  • Parathyroidectomy is generally a safe and effective procedure to treat many forms of hyperparathyroidism. (ahns.info)
  • Minimally invasive parathyroidectomy offers a reliable and less invasive approach for treating most patients with hyperparathyroidism. (ahns.info)
  • Reassessment of parathyroid hormone monitoring during parathyroidectomy for primary hyperparathyroidism after 2 preoperative localization studies. (atulgawande.com)
  • Estimated Effect of Parathyroidectomy on Long-Term Kidney Function in Adults With Primary Hyperparathyroidism. (stanford.edu)
  • pubMedId':'37983791','pubMedUrl':'https://www.ncbi.nlm.nih.gov/pubmed/37983791','publicationId':'894814','title':'Estimated Effect of Parathyroidectomy on Long-Term Kidney Function in Adults With Primary Hyperparathyroidism. (stanford.edu)
  • This prospective cohort study involved 6151 primary hyperparathyroidism patients registered in the Scandinavian Quality Registry of Thyroid , Parathyroid, and Adrenal surgery and the National Cancer Register after parathyroidectomy (exposure) during 2011-2017 ( patient cohort) and 60,654 individuals without primary hyperparathyroidism (reference cohort), matched by age, gender , and county of resident at the date of parathyroidectomy . (bvsalud.org)
  • Furthermore, patients with more severe primary hyperparathyroidism were more likely to have tooth extractions and periodontal interventions after parathyroidectomy . (bvsalud.org)
  • When used in a 90 year old patient with primary hyperparathyroidism it demonstrated a dramatic reduction in the calcium level which had proven difficult to reduce by bisphosphonates and who was not a candidate for surgical intervention. (touchendocrinology.com)
  • Over the past 30 years, there has been a shift in the clinical presentation of primary hyperparathyroidism from a disorder associated with overt skeletal and renal disease to an asymptomatic form. (amedi.sk)
  • Familial isolated hyperparathyroidism is an inherited condition characterized by overactivity of the parathyroid glands (hyperparathyroidism). (medlineplus.gov)
  • In people with familial isolated hyperparathyroidism, the production of excess parathyroid hormone is caused by tumors that involve the parathyroid glands. (medlineplus.gov)
  • Rarely, people with familial isolated hyperparathyroidism develop a cancerous tumor called parathyroid carcinoma. (medlineplus.gov)
  • Because the production of excess parathyroid hormone is caused by abnormalities of the parathyroid glands, familial isolated hyperparathyroidism is considered a form of primary hyperparathyroidism. (medlineplus.gov)
  • Disruption of the normal calcium balance resulting from overactive parathyroid glands causes many of the common signs and symptoms of familial isolated hyperparathyroidism, such as kidney stones , nausea, vomiting, high blood pressure ( hypertension ), weakness, and fatigue. (medlineplus.gov)
  • The age at which familial isolated hyperparathyroidism is diagnosed varies from childhood to adulthood. (medlineplus.gov)
  • The prevalence of familial isolated hyperparathyroidism is unknown. (medlineplus.gov)
  • Familial isolated hyperparathyroidism can be caused by mutations in the MEN1 , CDC73 , or CASR gene. (medlineplus.gov)
  • In familial isolated hyperparathyroidism, MEN1 gene mutations result in an altered menin protein that is no longer able to control cell growth and division. (medlineplus.gov)
  • Overproduction of parathyroid hormone from these abnormal glands stimulates the release of excess calcium into the blood, leading to the signs and symptoms of familial isolated hyperparathyroidism. (medlineplus.gov)
  • CDC73 gene mutations that cause familial isolated hyperparathyroidism likely result in decreased activity of the parafibromin protein. (medlineplus.gov)
  • CASR gene mutations associated with familial isolated hyperparathyroidism lead to the production of a less sensitive CaSR that requires an abnormally high concentration of calcium to trigger signaling. (medlineplus.gov)
  • Familial cases can occur as either part of the multiple endocrine neoplasia syndromes (MEN 1 or MEN 2a), hyperparathyroid-jaw tumor (HPT-JT) syndrome, or familial isolated hyperparathyroidism (FIHPT). (medscape.com)
  • Hyperparathyroidism occurs when overactive parathyroid glands cause levels of parathyroid hormone (PTH) in the blood to become elevated. (msdmanuals.com)
  • Biochemical confirmation of primary hyperparathyroidism is following by investigations to localize the culprit lesion. (wikipedia.org)
  • Imaging studies to detect parathyroid adenomas should be performed only after the diagnosis of primary HPT is established on the basis of biochemical findings. (medscape.com)
  • Neonatal primary hyperparathyroidism is a life threatening disorder that is associated with severe hypercalcaemia, hypotonia, bone demineralization, fractures and respiratory distress. (ox.ac.uk)
  • Primary hyperparathyroidism is a generalised disorder of calcium, phosphate and bone metabolism caused by long-lasting oversecretion of parathyroid hormone. (amedi.sk)
  • Tertiary hyperparathyroidism is a rare problem that can occur in patients after a kidney transplant. (ahns.info)
  • Less common are parathyroid hyperplasia (~2.5%), parathyroid carcinoma (malignant tumor), and adenomas in more than one gland (together ~0.5%).Primary hyperparathyroidism is also a feature of several familial endocrine disorders: Multiple endocrine neoplasia type 1 and type 2A (MEN type 1 and MEN type 2A), and familial hyperparathyroidism. (wikipedia.org)
  • Hyperparathyroidism can also be the result of hyperplasia of the parathyroid glands. (msdmanuals.com)
  • Some patients with primary hyperparathyroidism do not have any clearly related symptoms. (ahns.info)
  • In primary hyperparathyroidism due to adenomas, the normal feedback on parathyroid hormone production by extracellular calcium seems to be lost, resulting in a change in the set point. (medscape.com)
  • Dr. Seib has clinical and research expertise in the surgical management of endocrine disorders in older adults, including primary hyperparathyroidism, thyroid cancer, and hyperthyroidism. (stanford.edu)
  • Dr. Seib focuses on providing individualized care for patients with thyroid malignancy, hyperthyroidism, primary hyperparathyroidism, and adrenal disorders. (stanford.edu)
  • CONCLUSIONS: The proposed high spatial and temporal resolution 4D-dynamic contrast-enhanced MR imaging provides excellent diagnostic performance for preoperative localization in primary hyperparathyroidism, with correct gland localization of 92% for single- gland disease and 74% in multigland disease, superior to 4D-CT studies. (arizona.edu)
  • Skeletal changes after restoration of the euparathyroid state in patients with hypoparathyroidism and primary hyperparathyroidism. (unil.ch)
  • BACKGROUND AND PURPOSE: Our aim was to test the hypothesis that our recently introduced 4D-dynamic contrast-enhanced MR imaging with high spatial and temporal resolution has equivalent accuracy to 4D-CT for preoperative gland localization in primary hyperparathyroidism without requiring exposure to ionizing radiation. (arizona.edu)
  • Hypercalciuria was reintroduced as an indication for surgery at the 2013 Fourth International Workshop on the Management of Asymptomatic Primary Hyperparathyroidism. (medscape.com)
  • The primary response to parathyroid hormone (PTH) by the kidney is to increase renal calcium resorption and phosphate excretion. (handlebar-online.com)
  • Thus, this study aims to report a case of brown tumour of hyperparathyroidism surgically managed in a patient with chronic renal failure in dialysis, reviewing relevant concepts on the subject. (bvsalud.org)
  • Primary metabolic acidoses that occur as a result of a marked increase in endogenous acid production (eg, lactic or keto acids) or progressive accumulation of endogenous acids when excretion is impaired by renal insufficiency are characterized by decreased plasma bicarbonate concentration and increased anion gap without hyperchloremia. (medscape.com)
  • His medical history was remarkable for bilateral cystic-dysplastic kidneys, a congenital urethral valve (surgery in October 2006), terminal kidney insufficiency and peritoneal dialysis since 2006, renal anemia, hyperparathyroidism, hyperphosphatemia, microcephalus, and failure to thrive. (cdc.gov)
  • Clinical manifestations, radiographic findings, and bone mineral measurements of 65 patients with primary hyperparathyroidism are reviewed. (rsna.org)
  • Cinacalcet has been shown in patients with primary hyperparathyroidims in a double-blind randomised,placebo controlled trial to cause a fall in the serum calcium in a dose dependant manner. (endocrinesurgeon.co.uk)
  • The purpose of this project is to examine, in a non-inferiority study, whether the combination of conventional ultrasound and contrast-enhanced ultrasound (CEUS) can replace the radiation-based imaging modalities that are currently used to localise pathological parathyroid glands prior to surgical removal in patients with primary hyperparathyroidism. (rsyd.dk)
  • In most patients with primary hyperparathyroidism, one of the four glands is the cause of the problem. (ahns.info)
  • Bergqvist J, Iderberg H, Mesterton J, Bengtsson N, Wettermark B, Henriksson R. Healthcare resource use, comorbidity, treatment and clinical outcomes for patients with primary intracranial tumors: a Swedish population-based register study. (janusinfo.se)
  • However, primary hyperparathyroidism occurs when one or more parathyroid glands become enlarged and independently produce excess PTH. (masseyeandear.org)
  • Hyperparathyroidism occurs when one or more of your parathyroid glands becomes overly active and releases too much PTH. (healthline.com)
  • Neonatal primary hyperparathyroidism masked by vitamin D deficiency. (ox.ac.uk)
  • An elevated intact parathyroid hormone level with an elevated ionized serum calcium level is diagnostic of primary hyperparathyroidism. (medscape.com)
  • The diagnostics of primary hyperparathyroidism became much easier by introduction of assessment of intact parathyroid hormone into routine practice. (amedi.sk)
  • Hyperparathyroidism is a disease characterized by excessive secretion of parathyroid hormone, an 84-amino acid polypeptide hormone. (medscape.com)
  • The diagnosis of primary hyperparathyroidism is made by blood tests. (wikipedia.org)
  • Surgery is the definitive treatment for primary hyperparathyroidism. (masseyeandear.org)
  • There is hope yet for a satisfactory medical treatment for hyperparathyroidism that will make surgery obsolete! (endocrinesurgeon.co.uk)
  • [ 1 ] However, in practice, some patients with mild to moderate hyperparathyroidism and hypercalciuria are ineligible for surgery or refuse surgical procedures. (medscape.com)
  • In most patients, treatment for primary hyperparathyroidism is parathyroid surgery. (ahns.info)
  • While, this type of hyperparathyroidism often can be controlled with medication some patients may need parathyroid surgery to lower the level of PTH. (ahns.info)
  • In these patients their hyperparathyroidism returns or their first surgery was not successful in curing their disease. (ahns.info)
  • Other bone diseases associated with hyperparathyroidism are osteoporosis, osteomalacia, and arthritis. (wikipedia.org)
  • Because calcium is removed from bones to be released into the bloodstream, hyperparathyroidism often causes thinning of the bones ( osteoporosis ). (medlineplus.gov)
  • If not treated primary hyperparathyroidism can lead to kidney damage and stones and weak bones (osteoporosis). (ahns.info)
  • Herein, we present a 59-year-old male patient with PG developed as a result of zoledronic acid (ZA) infusion, which was administered due to primary hyperparathyroidism. (ftrdergisi.com)
  • The calcium levels are rarely very high and there is very little calcium in the urine, allowing the experienced clinician to differentiate it from primary hyperparathyroidism. (endocrinesurgeon.co.uk)
  • Primary hyperparathyroidism (HPT) is a condition characterized by an inappropriate excess of parathyroid hormone (PTH) secretion. (medscape.com)
  • Primary hyperparathyroidism in adults-(Part I) assessment and medical management: Position statement of the endocrine society of Australia, the Australian & New Zealand endocrine surgeons, and the Australian & New Zealand bone and mineral society. (austin.org.au)
  • Surgical excision of abnormal parathyroid glands offers the only permanent, curative treatment for primary hyperparathyroidism. (medscape.com)
  • Moreover, as second step, they found that in patients affected by primary hyperparathyroidism condition (having chronic high PTH), Irisin blood levels are reduced up one third compared to controls. (ects-academy.org)
  • citation needed] Recently, it was demonstrated that liquidators of the Chernobyl power plant are faced with a substantial risk of primary hyperparathyroidism, possibly caused by radioactive strontium isotopes. (wikipedia.org)
  • Lim, V & Clarke, BL 2013, ' Coexisting primary hyperparathyroidism and sarcoidosis cause increased angiotensin-converting enzyme and decreased parathyroid hormone and phosphate levels ', Journal of Clinical Endocrinology and Metabolism , vol. 98, no. 5, pp. 1939-1945. (elsevierpure.com)
  • There was in the past no effective medical treatment to control primary hyperparathyroidism. (endocrinesurgeon.co.uk)
  • Although there is no effective medical treatment for hyperparathyroidism, there are novel developments that involve the parathyroid calcium sensor (calcium receptor). (endocrinesurgeon.co.uk)
  • This is the best form of treatment for primary hyperparathyroidism. (endocrinesurgeon.co.uk)
  • To the best of our knowledge, this is the first case report of a PG attack after ZA treatment for primary hyperparathyroidism. (ftrdergisi.com)
  • Successful surgical treatment of hyperparathyroidism not only requires sophisticated technology and specialized skills, but also teamwork between the endocrinologist and endocrine surgeon. (mhs.net)
  • Over time, the parathyroid glands become hyperplastic and less susceptible to treatment with calcium and calcitriol, producing a continuous secret ion of PTH and result ing secondar y hyperparathyroidism 3 . (bvsalud.org)
  • Primary purpose: Treatment. (who.int)
  • Genetic testing for familial hyperparathyroidism is recommended in selected patients. (austin.org.au)
  • 4.Cinacalcet, a drug that sensitizes the calcium receptor to the ambient serum calcium used long term will reduce the serum calcium to normal levels in primary hyperparathyroidism but as yet has not been shown to significantly increase bone density. (endocrinesurgeon.co.uk)